

**METHODS OF USING AND COMPOSITIONS COMPRISING
A JNK INHIBITOR FOR THE TREATMENT,
PREVENTION, MANAGEMENT AND/OR MODIFICATION OF PAIN**

This application claims the benefit of U.S. provisional application no. 60/421,104, filed October 24, 2002, the contents of which are incorporated by reference herein in their entirety.

10 **1. FIELD OF INVENTION**

This invention relates to methods for treating, preventing, modifying and/or managing pain and related syndromes, which comprise the administration of a JNK Inhibitor alone or in combination with known therapeutics or therapies. The invention also relates to pharmaceutical compositions comprising a JNK Inhibitor and
15 dosing regimens.

2. BACKGROUND OF THE INVENTION

Pain is the leading symptom of many different disorders and is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. *Classification of Chronic Pain*,
20 International Association for the Study of Pain (IASP) Task Force on Taxonomy, Merskey H, Bogduk N, eds., IASP Press: Seattle, 209-214, 1994. Because the perception of pain is highly subjective, it is one of the most difficult pathologies to diagnose and treat effectively. Pain leads to severe impairment of functional ability, which compromises the working, social, and family lives of sufferers. Around five percent of
25 the adult population is estimated to suffer from pain sufficiently severe to cause significant disability. Chojnowska E, Stannard C. *Epidemiology of Chronic Pain*, Chapter 2, pp 15-26; T.S. Jensen, P.R. Wilson, A.S.C. Rice eds., Clinical Pain Management Chronic Pain, Arnold, London, 2003.

In most pain conditions, there is increased neural input from the
30 periphery. Sensory nerve impulses travel via the axons of primary afferent neurons to the dorsal horn of the spinal cord, where they propagate nerve impulses to dorsal horn neurons by releasing excitatory amino acids and neuropeptides at synapses. Dorsal horn projection neurons process and transfer the information about a peripheral stimuli to the

5 brain via ascending spinal pathways. Mannion, R.J. and Woolf, C.J., *Clin. J. of Pain* 16:S144-S156 (2000).

The firing of dorsal horn projection neurons is determined not only by the excitatory input they receive, but also by inhibitory input from the spinal cord and higher nerve centers. Several brain regions contribute to descending inhibitory pathways. Nerve
10 fibers from these pathways release inhibitory substances such as endogenous opioids, γ -aminobutyric acid (GABA), and serotonin at synapses with other neurons in the dorsal horn or primary afferent neurons and inhibit nociceptive transmission. Peripheral nerve injury can produce changes in dorsal horn excitability by down-regulating the amount of inhibitory control over dorsal horn neurons through various mechanisms.

15 Repeated or prolonged stimulation of dorsal horn neurons due to C-nociceptor activation or damaged nerves can cause a prolonged increase in dorsal horn neuron excitability and responsiveness that can last hours longer than the stimulus. Sensitization of the dorsal horn neurons increases their excitability such that they respond to normal input in an exaggerated and extended way. It is now known that such
20 sustained activity in primary afferent C-fibers leads to both morphological and biochemical changes in the dorsal horn which may be difficult to reverse. Several changes in the dorsal horn have been noted to occur with central sensitization: (i) an expansion of the dorsal horn receptive field size so that a spinal neuron will respond to noxious stimuli outside the region normally served by that neuron ; (ii) an increase in
25 the magnitude and duration of the response to a given noxious stimulus (hyperalgesia); (iii) a painful response to a normally innocuous stimulus, for example, from a mechanoreceptive primary afferent A β -fibre (allodynia); and (iv) the spread of pain to uninjured tissue (referred pain). Koltzenburg, M. *Clin. J. of Pain* 16:S131-S138 (2000); Mannion, R.J. and Woolf, C.J., *Clin. J. of Pain* 16:S144-S156 (2000).

30 Central sensitization may explain, in part, the continuing pain and hyperalgesia that occurs following an injury and may serve an adaptive purpose by encouraging protection of the injury, during the healing phase. Central sensitization however can persist long after the injury has healed thereby supporting chronic pain. Sensitization also plays a key role in chronic pain, helping to explain why it often
35 exceeds the provoking stimulus, both spatially and temporally, and may help explain

5 why established pain is more difficult to suppress than acute pain. Koltzenburg, M. *Clin. J. of Pain* 16:S131-S138 (2000).

Accordingly, safe and effective methods for the treatment, prevention, modification or management of pain are needed.

2.1 TYPES OF PAIN

10 2.1.1 Nociceptive Pain

Nociceptive pain is elicited when noxious stimuli such as inflammatory chemical mediators are released following tissue injury, disease, or inflammation and are detected by normally functioning sensory receptors (nociceptors) at the site of injury. Koltzenburg, M. *Clin. J. of Pain* 16:S131-S138 (2000). Clinical examples of nociceptive
15 pain include, but are not limited to, pain associated with chemical or thermal burns, cuts and contusions of the skin, osteoarthritis, rheumatoid arthritis, tendonitis, and myofascial pain.

Nociceptors (sensory receptors) are distributed throughout the periphery of tissue. They are sensitive to noxious stimuli (*e.g.*, thermal, mechanical, or chemical)
20 which would damage tissue if prolonged. Activation of peripheral nociceptors by such stimuli excites discharges in two distinct types of primary afferent neurons: slowly conducting unmyelinated c-fibers and more rapidly conducting, thinly myelinated A δ fibers. C-fibers are associated with burning pain and A δ fibers with stabbing pain. Koltzenburg, M. *Clin. J. of Pain* 16:S131-S138 (2000); Besson, J.M. *Lancet* 353:1610-
25 15 (1999); Johnson, B.W. *Pain Mechanisms: Anatomy, Physiology and Neurochemistry*, Chapter 11 in Practical Management of Pain ed. P. Prithvi Raj. (3rd Ed., Mosby, Inc., St Louis, 2000). Most nociceptive pain involves signaling from both A δ and c-types of primary afferent nerve fibers.

Peripheral nociceptors are sensitized by inflammatory mediators such as prostaglandin, substance P, bradykinin, histamine, and serotonin, as well as by intense,
30 repeated, or prolonged noxious stimulation. In addition, cytokines and growth factors (*e.g.*, nerve growth factor) can influence neuronal phenotype and function. Besson, J.M. *Lancet* 353:1610-15 (1999).

When sensitized, nociceptors exhibit a lower activation threshold and an
35 increased rate of firing, which means that they generate nerve impulses more readily and

5 more frequently. Peripheral sensitization of nociceptors plays an important role in spinal
cord dorsal horn central sensitization and clinical pain states such as hyperalgesia and
allodynia.

Inflammation also appears to have another important effect on peripheral
nociceptors. Some C-nociceptors do not normally respond to any level of mechanical or
10 thermal stimuli, and are only activated in the presence of inflammation or in response to
tissue injury. Such nociceptors are called “silent” nociceptors, and have been identified
in visceral and cutaneous tissue. Besson, J.M. *Lancet* 353:1610-15 (1999); Koltzenburg,
M. *Clin. J. of Pain* 16:S131-S138 (2000).

Differences in how noxious stimuli are processed across different tissues
15 contribute to the varying characteristics of nociceptive pain. For example, cutaneous
pain is often described as a well-localized sharp, prickling, or burning sensation whereas
deep somatic pain may be described as diffuse, dull, or an aching sensation. In general,
there is a variable association between pain perception and stimulus intensity, as the
central nervous system and general experience influence the perception of pain.

20 **2.1.2 Neuropathic Pain**

Neuropathic pain reflects injury or impairment of the nervous system, and
has been defined by the IASP as “pain initiated or caused by a primary lesion or
dysfunction in the nervous system”. *Classification of Chronic Pain*, International
Association for the Study of Pain (IASP) Task Force on Taxonomy, Merskey H, Bogduk
25 N, eds., IASP Press: Seattle, 209-214, 1994. Some neuropathic pain is caused by injury
or dysfunction of the peripheral nervous system. As a result of injury, changes in the
expression of key transducer molecules, transmitters, and ion channels occur, leading to
altered excitability of peripheral neurons. Johnson, B.W. *Pain Mechanisms: Anatomy,
Physiology and Neurochemistry*, Chapter 11 in Practical Management of Pain ed. P.
30 Prithvi Raj. (3rd Ed., Mosby, Inc., St Louis, 2000). Clinical examples of neuropathic
pain include, but are not limited to, pain associated with diabetic neuropathy,
postherpetic neuralgia, trigeminal neuralgia, and post-stroke pain.

Neuropathic pain is commonly associated with several distinct
characteristics, such as pain which may be continuous or episodic and is described in
35 many ways, such as burning, tingling, prickling, shooting, electric-shock-like, jabbing,

5 squeezing, deep aching, or spasmodic. Paradoxically partial or complete sensory deficit
is often present in patients with neuropathic pain who experience diminished perception
of thermal and mechanical stimuli. Abnormal or unfamiliar unpleasant sensations
(dysaesthesias) may also be present and contribute to suffering. Other features are the
ability of otherwise non-noxious stimuli to produce pain (allodynia) or the
10 disproportionate perception of pain in response to supra-threshold stimuli (hyperalgesia).
Johnson, B.W. *Pain Mechanisms: Anatomy, Physiology and Neurochemistry*, Chapter
11 in Practical Management of Pain ed. P. Prithvi Raj. (3rd Ed., Mosby, Inc., St Louis,
2000(; Attal, N. *Clin. J. of Pain* 16:S118-S130 (2000).

Complex regional pain syndrome (CRPS) is a type of neuropathic pain
15 which usually affects the extremities in the absence (CRPS type I) or presence (CRPS
type II) of a nerve injury. CRPS type I encompasses the condition known as reflex
sympathetic dystrophy (RSD), CRPS type II encompasses the condition known as
causalgia and both types have subsets consistent with sympathetic maintained pain
syndrome. In 1993, a special consensus conference of the IASP addressed diagnosis and
20 terminology of the disease, and endorsed the term CRPS with the two subtypes.
Subsequent studies and conferences have refined the definitions such that the current
guidelines give high sensitivity (0.70) with very high specificity (0.95). Bruehl, *et al.*
Pain 81:147-154 (1999). However, there is still no general agreement on what causes
the disease, or how best to treat it. Paice, E., *British Medical Journal* 310: 1645-1648
25 (1995).

CRPS is a multi-symptom and multi-system syndrome affecting multiple
neural, bone and soft tissues, including one or more extremities, which is characterized
by an intense pain. Although it was first described 130 years ago, CRPS remains poorly
understood. For example, changes in peripheral and central somatosensory, autonomic,
30 and motor processing, and a pathologic interaction of sympathetic and afferent systems
have been proposed as underlying mechanisms. Wasner *et al.* demonstrated a complete
functional loss of cutaneous sympathetic vasoconstrictor activity in an early stage of
CRPS with recovery. Wasner G., Heckmann K., Maier C., *Arch Neurol* 56(5): 613-20
(1999). Kurvers *et al.* suggested a spinal component to microcirculatory abnormalities at
35 stage I of CRPS, which appeared to manifest itself through a neurogenic inflammatory

5 mechanism. Kurvers H.A., Jacobs M.J., Beuk R.J., *Pain* 60(3): 333-40 (1995). The cause of vascular abnormalities is unknown, and debate still surrounds the question of whether the sympathetic nervous system (SNS) is involved in the generation of these changes.

The actual incidence of CRPS in the U.S. is unknown, and limited
10 information is available about the epidemiology of the disease. Both sexes are affected, but the incidence of the syndrome is higher in women. The syndrome may occur in any age group, including the pediatric population. Schwartzman R.J., *Curr Opin Neurol Neurosurg* 6(4): 531-6 (1993). Various causes that have led to CRPS include, but are not limited to, head injury, stroke, polio, tumor, trauma, amyotrophic lateral sclerosis
15 (ALS), myocardial infarction, polymyalgia rheumatica, operative procedure, brachial plexopathy, cast/splint immobilization, minor extremity injury and malignancy.

Symptoms of CRPS include, but are not limited to, pain, autonomic dysfunction, edema, movement disorder, dystrophy, and atrophy. Schwartzman R.J., *N Engl J Med* 343(9): 654-6 (2000). The pain is described as extremely severe and
20 unrelenting, often with a burning character. Ninety percent of all CRPS patients complain of spontaneous burning pain and allodynia, which refers to pain with light touch. Much of the difficulty clinicians have with this syndrome is the fact that pain may be far worse than what would be expected based on physical findings. *Id.* Pain is also accompanied by swelling and joint tenderness, increased sweating, sensitivity to
25 temperature and light touch, as well as color change to the skin. In fact, the diagnosis of CRPS cannot be made on reports of pain alone. Patients must have signs and symptoms of sensory abnormalities as well as vascular dysfunction accompanied by excessive sweating, edema or trophic changes to the skin.

As mentioned above, the IASP has divided CRPS into two types, namely
30 CRPS type I (also referred to as RSD) and CRPS type II (also referred to as causalgia). These two types are differentiated mainly based upon whether the inciting incident included a definable nerve injury. CRPS type I occurs after an initial noxious event other than a nerve injury. CRPS type II occurs after nerve injury. CRPS is further divided into distinct stages in its development and manifestation. However, the course of
35 the disease seems to be so unpredictable between various patients that staging is not

5 always clear or helpful in treatment. Schwartzman R.J., *N Engl J Med* 343(9): 654 (2000).

In stage I, or “early RSD,” pain is more severe than would be expected from the injury, and it has a burning or aching quality. It may be increased by dependency of the limb, physical contact, or emotional upset. The affected area typically becomes edematous, may be hyperthermic or hypothermic, and may show increased nail and hair growth. Radiographs may show early bony changes. *Id.*

In stage II, or “established RSD,” edematous tissue becomes indurated. Skin typically becomes cool and hyperhidrotic with livedo reticularis or cyanosis. Hair may be lost, and nails become ridged, cracked, and brittle. Hand dryness becomes prominent, and atrophy of skin and subcutaneous tissues becomes noticeable. Pain remains the dominant feature. It is usually constant and is increased by any stimulus to the affected area. Stiffness develops at this stage. Radiographs may show diffuse osteoporosis. *Id.*

In stage III, or “late RSD,” pain spreads proximally. Although it may diminish in intensity, pain remains a prominent feature. Flare-ups may occur spontaneously. Irreversible tissue damage occurs, and the skin is typically thin and shiny. Edema is absent, but contractures may occur. X-ray films typically indicate marked bone demineralization. *Id.*

In all stages of CRPS, patients endure severe chronic pain and most patients are sleep deprived. CRPS has significant morbidity and thus raising awareness of the disease is important. Early and effective treatment may lessen the effect of CRPS in some individuals. William D. Dzwierzynski *et al.*, *Hand Clinics* Vol 10 (1): 29-44 (1994).

2.1.3 Other Types of Pain

Visceral pain has been conventionally viewed as a variant of somatic pain, but may differ in neurological mechanisms. Visceral pain is also thought to involve silent nociceptors, visceral afferent fibers that only become activated in the presence of inflammation. Cervero, F. and Laird J.M.A., *Lancet* 353:2145-48 (1999).

Certain clinical characteristics are peculiar to visceral pain: (i) it is not evoked from all viscera and not always linked to visceral injury; (ii) it is often diffuse

5 and poorly localized, due to the organization of visceral nociceptive pathways in the central nervous system (CNS), particularly the absence of a separate visceral sensory pathway and the low proportion of visceral afferent nerve fibers; (iii) it is sometimes referred to other non-visceral structures; and (iv) it is associated with motor and autonomic reflexes, such as nausea. Johnson, B.W. *Pain Mechanisms: Anatomy,*
10 *Physiology and Neurochemistry*, Chapter 11 in Practical Management of Pain ed. P. Prithvi Raj. (3rd Ed., Mosby, Inc., St Louis, 2000); Cervero, F. and Laird J.M.A., *Lancet* 353:2145-48 (1999).

Headaches can be classified as primary and secondary headache disorders. The pathophysiology of the two most common primary disorders, migraine and tension-
15 type headache, is complex and not fully understood. Recent studies indicate that nociceptive input to the CNS may be increased due to the activation and sensitization of peripheral nociceptors, and the barrage of nociceptive impulses results in the activation and sensitization of second- and third-order neurons in the CNS. Thus, it is likely that central sensitization plays a role in the initiation and maintenance of migraine and
20 tension-type headache. Johnson, B.W. *Pain Mechanisms: Anatomy, Physiology and Neurochemistry*, Chapter 11 in Practical Management of Pain ed. P. Prithvi Raj. (3rd Ed., Mosby, Inc., St Louis, 2000).

Post-operative pain, such as that resulting from trauma to tissue caused during surgery, produces a barrage of nociceptive input. Following surgery, there is an
25 inflammatory response at the site of injury involving cytokines, neuropeptides and other inflammatory mediators. These chemical are responsible for the sensitization and increased responsiveness to external stimuli, resulting in, for example, lowering of the threshold and an increased response to supra-threshold stimuli. Together, these processes result in peripheral and central sensitization. Johnson, B.W. *Pain Mechanisms:*
30 *Anatomy, Physiology and Neurochemistry*, Chapter 11 in Practical Management of Pain ed. P. Prithvi (Raj. 3rd Ed., Mosby, Inc., St Louis, 2000).

Mixed pain is chronic pain that has nociceptive and neuropathic components. For example, a particular pain can be initiated through one pain pathway and sustained through a different pain pathway. Examples of mixed pain states include,
35 but are not limited to, cancer pain and low back pain.

5

2.2 CURRENT TREATMENTS FOR PAIN

Current treatment for CRPS related pain in particular and chronic pain in general includes pain management and extensive physical therapy, which can help to prevent edema and joint contractures and can also help to minimize pain. Often, medication and neural blockade are used to help with the severe pain. Regional neural blockade is performed using Bier blocks with a variety of agents, including local anesthetics, bretylium, steroids, calcitonin, reserpine, and guanethidine. Perez, R.S., *et al.*, *J. Pain Symptom Manage* 21(6): 511-26 (2001). Specific, selective sympathetic ganglia neural blockade is performed for both diagnostic and therapeutic purposes. The rationale for selective neural blockade is to interrupt the sympathetic nervous system and reduce the activation of the sensory nerves. Patients who fail well-controlled neural blockade treatment may have pain that is sympathetic-independent. Once refractory to neural blockade, pain is typically lifelong and may be severe enough to be debilitating. *Id.*

Medications presently used during the treatment of chronic pain in general include calcium channel blockers, muscle relaxants, non-narcotic analgesics, opioid analgesics, and systemic corticosteroids. However, patients rarely obtain complete pain relief. Moreover, because the mechanisms of pain and autonomic dysfunction are poorly understood, the treatments are completely empirical. Therefore, there remains a need for safe and effective methods of treating and managing pain.

25

3. SUMMARY OF THE INVENTION

The present invention relates to methods for treating or preventing pain, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a JNK Inhibitor. The invention also relates to methods for managing (*e.g.*, lengthening the time of remission) pain, which comprise administering to a patient in need of such management a therapeutically or prophylactically effective amount of a JNK Inhibitor. The invention further relates to methods for modifying pain, which comprise administering to a patient in need thereof a therapeutically or prophylactically effective amount of a JNK Inhibitor.

Another embodiment of the invention encompasses the use of one or more JNK Inhibitors with another therapeutic useful for the treatment, prevention,

5 management and/or modification of pain such as, but not limited to, an antidepressant,
antihypertensive, anxiolytic, calcium channel blocker, muscle relaxant, non-narcotic
analgesic, anti-inflammatory agent, cox-2 inhibitor, alpha-adrenergic receptor agonist or
antagonist, ketamine, anesthetics, immunomodulatory agent, immunosuppressive agent,
corticosteroid, hyperbaric oxygen, anticonvulsant, an IMiD[®], a SelCID[®], or a
10 combination thereof.

Yet another embodiment of the invention encompasses the use of one or
more JNK Inhibitors in combination with conventional therapies used to treat, prevent,
manage and/or modify pain including, but not limited to, surgery, interventional
procedures (*e.g.*, neural blockade), physical therapy, and psychological therapy.

15 The invention further encompasses pharmaceutical compositions, single
unit dosage forms, and kits suitable for use in treating, preventing, managing and/or
modifying pain, which comprise a therapeutically or prophylactically effective amount of
a JNK Inhibitor.

3.1 DEFINITIONS

20 As used herein, the term “patient” means an animal (*e.g.*, cow, horse,
sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig), preferably a
mammal such as a non-primate and a primate (*e.g.*, monkey and human), most preferably
a human.

“Alkyl” means a saturated straight chain or branched non-cyclic
25 hydrocarbon having from 1 to 10 carbon atoms. “Lower alkyl” means alkyl, as defined
above, having from 1 to 4 carbon atoms. Representative saturated straight chain alkyls
include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-
nonyl and -n-decyl; while saturated branched alkyls include -isopropyl, -*sec*-butyl, -
isobutyl, -*tert*-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-
30 methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-
methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-
dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, 2,2-
dimethylhexyl, 3,3-dimethylpentyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl,
3-ethylpentyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-
35 methyl-3-ethylpentyl, 2-methyl-4-ethylpentyl, 2-methyl-2-ethylhexyl, 2-methyl-3-

5 ethylhexyl, 2-methyl-4-ethylhexyl, 2,2-diethylpentyl, 3,3-diethylhexyl, 2,2-diethylhexyl, 3,3-diethylhexyl and the like.

An “alkenyl group” or “alkylidene” mean a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon double bond. Representative straight chain and branched (C₂-
10 C₁₀)alkenyls include -vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, -1-hexenyl, -2-hexenyl, -3-hexenyl, -1-heptenyl, -2-heptenyl, -3-heptenyl, -1-octenyl, -2-octenyl, -3-octenyl, -1-nonenyl, -2-nonenyl, -3-nonenyl, -1-decenyl, -2-decenyl, -3-decenyl and the like. An alkenyl group can be unsubstituted or substituted. A “cyclic
15 alkylidene” is a ring having from 3 to 8 carbon atoms and including at least one carbon-carbon double bond, wherein the ring can have from 1 to 3 heteroatoms.

An “alkynyl group” means a straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon triple bond. Representative straight chain and branched -(C₂-C₁₀)alkynyls include -
20 acetylenyl, -propynyl, -1-butyne, -2-butyne, -1-pentyne, -2-pentyne, -3-methyl-1-butyne, -4-pentyne, -1-hexynyl, -2-hexynyl, -5-hexynyl, -1-heptyne, -2-heptyne, -6-heptyne, -1-octynyl, -2-octynyl, -7-octynyl, -1-nonyne, -2-nonyne, -8-nonyne, -1-decynyl, -2-decynyl, -9-decynyl, and the like. An alkynyl group can be unsubstituted or substituted.

25 The terms “Halogen” and “Halo” mean fluorine, chlorine, bromine or iodine.

“Haloalkyl” means an alkyl group, wherein alkyl is defined above, substituted with one or more halogen atoms.

“Keto” means a carbonyl group (*i.e.*, C=O).

30 “Acyl” means an -C(O)alkyl group, wherein alkyl is defined above, including -C(O)CH₃, -C(O)CH₂CH₃, -C(O)(CH₂)₂CH₃, -C(O)(CH₂)₃CH₃, -C(O)(CH₂)₄CH₃, -C(O)(CH₂)₅CH₃, and the like.

“Acyloxy” means an -OC(O)alkyl group, wherein alkyl is defined above, including -OC(O)CH₃, -OC(O)CH₂CH₃, -OC(O)(CH₂)₂CH₃, -OC(O)(CH₂)₃CH₃, -
35 OC(O)(CH₂)₄CH₃, -OC(O)(CH₂)₅CH₃, and the like.

5 “Ester” means and -C(O)Oalkyl group, wherein alkyl is defined above, including -C(O)OCH₃, -C(O)OCH₂CH₃, -C(O)O(CH₂)₂CH₃, -C(O)O(CH₂)₃CH₃, -C(O)O(CH₂)₄CH₃, -C(O)O(CH₂)₅CH₃, and the like.

 “Alkoxy” means -O-(alkyl), wherein alkyl is defined above, including -OCH₃, -OCH₂CH₃, -O(CH₂)₂CH₃, -O(CH₂)₃CH₃, -O(CH₂)₄CH₃, -O(CH₂)₅CH₃, and the like. “Lower alkoxy” means -O-(lower alkyl), wherein lower alkyl is as described above.

10 “Alkoxyalkoxy” means -O-(alkyl)-O-(alkyl), wherein each alkyl is independently an alkyl group defined above, including -OCH₂OCH₃, -OCH₂CH₂OCH₃, -OCH₂CH₂OCH₂CH₃, and the like.

 “Alkoxycarbonyl” means -C(=O)O-(alkyl), wherein alkyl is defined above, including -C(=O)O-CH₃, -C(=O)O-CH₂CH₃, -C(=O)O-(CH₂)₂CH₃, -C(=O)O-(CH₂)₃CH₃, -C(=O)O-(CH₂)₄CH₃, -C(=O)O-(CH₂)₅CH₃, and the like.

15 “Alkoxycarbonylalkyl” means -(alkyl)-C(=O)O-(alkyl), wherein each alkyl is independently defined above, including -CH₂-C(=O)O-CH₃, -CH₂-C(=O)O-CH₂CH₃, -CH₂-C(=O)O-(CH₂)₂CH₃, -CH₂-C(=O)O-(CH₂)₃CH₃, -CH₂-C(=O)O-(CH₂)₄CH₃, -CH₂-C(=O)O-(CH₂)₅CH₃, and the like.

20 “Alkoxyalkyl” means -(alkyl)-O-(alkyl), wherein each alkyl is independently an alkyl group defined above, including -CH₂OCH₃, -CH₂OCH₂CH₃, -(CH₂)₂OCH₂CH₃, -(CH₂)₂O(CH₂)₂CH₃, and the like.

 “Aryl” means a carbocyclic aromatic group containing from 5 to 10 ring atoms. Representative examples include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, pyridinyl and naphthyl, as well as benzo-fused carbocyclic moieties including 5,6,7,8-tetrahydronaphthyl. A carbocyclic aromatic group can be unsubstituted or substituted. In one embodiment, the carbocyclic aromatic group is a phenyl group.

25 “Aryloxy” means -O-aryl group, wherein aryl is as defined above. An aryloxy group can be unsubstituted or substituted. In one embodiment, the aryl ring of an aryloxy group is a phenyl group

30 “Arylalkyl” means -(alkyl)-(aryl), wherein alkyl and aryl are as defined above, including -(CH₂)phenyl, -(CH₂)₂phenyl, -(CH₂)₃phenyl, -CH(phenyl)₂, -

5 CH(phenyl)₃, -(CH₂)tolyl, -(CH₂)anthracenyl, -(CH₂)fluorenyl, -(CH₂)indenyl, -(CH₂)azulenyl, -(CH₂)pyridinyl, -(CH₂)naphthyl, and the like.

“Arylalkyloxy” means -O-(alkyl)-(aryl), wherein alkyl and aryl are defined above, including -O-(CH₂)₂phenyl, -O-(CH₂)₃phenyl, -O-CH(phenyl)₂, -O-CH(phenyl)₃, -O-(CH₂)tolyl, -O-(CH₂)anthracenyl, -O-(CH₂)fluorenyl, -O-
10 (CH₂)indenyl, -O-(CH₂)azulenyl, -O-(CH₂)pyridinyl, -O-(CH₂)naphthyl, and the like.

“Aryloxyalkyl” means -(alkyl)-O-(aryl), wherein alkyl and aryl are defined above, including -CH₂-O-(phenyl), -(CH₂)₂-O-phenyl, -(CH₂)₃-O-phenyl, -(CH₂)-O-tolyl, -(CH₂)-O-anthracenyl, -(CH₂)-O-fluorenyl, -(CH₂)-O-indenyl, -(CH₂)-O-azulenyl, -(CH₂)-O-pyridinyl, -(CH₂)-O-naphthyl, and the like.

15 “Cycloalkyl” means a monocyclic or polycyclic saturated ring having carbon and hydrogen atoms and having no carbon-carbon multiple bonds. Examples of cycloalkyl groups include, but are not limited to, (C₃-C₇)cycloalkyl groups, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, and saturated cyclic and bicyclic terpenes. A cycloalkyl group can be unsubstituted or substituted. In one
20 embodiment, the cycloalkyl group is a monocyclic ring or bicyclic ring.

“Cycloalkyloxy” means -O-(cycloalkyl), wherein cycloalkyl is defined above, including -O-cyclopropyl, -O-cyclobutyl, -O-cyclopentyl, -O-cyclohexyl, -O-cycloheptyl and the like.

“Cycloalkylalkyloxy” means -O-(alkyl)-(cycloalkyl), wherein cycloalkyl
25 and alkyl are defined above, including -O-CH₂-cyclopropyl, -O-(CH₂)₂-cyclopropyl, -O-(CH₂)₃-cyclopropyl, -O-(CH₂)₄-cyclopropyl, O-CH₂-cyclobutyl, O-CH₂-cyclopentyl, O-CH₂-cyclohexyl, O-CH₂-cycloheptyl, and the like.

“Aminoalkoxy” means -O-(alkyl)-NH₂, wherein alkyl is defined above, such as -O-CH₂-NH₂, -O-(CH₂)₂-NH₂, -O-(CH₂)₃-NH₂, -O-(CH₂)₄-NH₂, -O-(CH₂)₅-NH₂,
30 and the like.

“Mono-alkylamino” means -NH(alkyl), wherein alkyl is defined above, such as -NHCH₃, -NHCH₂CH₃, -NH(CH₂)₂CH₃, -NH(CH₂)₃CH₃, -NH(CH₂)₄CH₃, -NH(CH₂)₅CH₃, and the like.

5 “Di-alkylamino” means -N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -N(CH₃)₂, -N(CH₂CH₃)₂, -N((CH₂)₂CH₃)₂, -N(CH₃)(CH₂CH₃), and the like.

 “Mono-alkylaminoalkoxy” means -O-(alkyl)-NH(alkyl), wherein each alkyl is independently an alkyl group defined above, including -O-(CH₂)-NHCH₃, -O-(CH₂)-NHCH₂CH₃, -O-(CH₂)-NH(CH₂)₂CH₃, -O-(CH₂)-NH(CH₂)₃CH₃, -O-(CH₂)-NH(CH₂)₄CH₃, -O-(CH₂)-NH(CH₂)₅CH₃, -O-(CH₂)₂-NHCH₃, and the like.

 “Di-alkylaminoalkoxy” means -O-(alkyl)-N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -O-(CH₂)-N(CH₃)₂, -O-(CH₂)-N(CH₂CH₃)₂, -O-(CH₂)-N((CH₂)₂CH₃)₂, -O-(CH₂)-N(CH₃)(CH₂CH₃), and the like.

 “Arylamino” means -NH(aryl), wherein aryl is defined above, including -NH(phenyl), -NH(tolyl), -NH(anthracenyl), -NH(fluorenyl), -NH(indenyl), -NH(azulenyl), -NH(pyridinyl), -NH(naphthyl), and the like.

 “Arylalkylamino” means -NH-(alkyl)-(aryl), wherein alkyl and aryl are defined above, including -NH-CH₂-(phenyl), -NH-CH₂-(tolyl), -NH-CH₂-(anthracenyl), -NH-CH₂-(fluorenyl), -NH-CH₂-(indenyl), -NH-CH₂-(azulenyl), -NH-CH₂-(pyridinyl), -NH-CH₂-(naphthyl), -NH-(CH₂)₂-(phenyl) and the like.

 “Alkylamino” means mono-alkylamino or di-alkylamino as defined above, such as -N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -N(CH₃)₂, -N(CH₂CH₃)₂, -N((CH₂)₂CH₃)₂, -N(CH₃)(CH₂CH₃) and -N(alkyl)(alkyl), wherein each alkyl is independently an alkyl group defined above, including -N(CH₃)₂, -N(CH₂CH₃)₂, -N((CH₂)₂CH₃)₂, -N(CH₃)(CH₂CH₃) and the like.

 “Cycloalkylamino” means -NH-(cycloalkyl), wherein cycloalkyl is as defined above, including -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-cyclohexyl, -NH-cycloheptyl, and the like.

 “Carboxyl” and “carboxy” mean -COOH.

 “Cycloalkylalkylamino” means -NH-(alkyl)-(cycloalkyl), wherein alkyl and cycloalkyl are defined above, including -NH-CH₂-cyclopropyl, -NH-CH₂-cyclobutyl, -NH-CH₂-cyclopentyl, -NH-CH₂-cyclohexyl, -NH-CH₂-cycloheptyl, -NH-(CH₂)₂-cyclopropyl and the like.

5 “Aminoalkyl” means -(alkyl)-NH₂, wherein alkyl is defined above,
including CH₂-NH₂, -(CH₂)₂-NH₂, -(CH₂)₃-NH₂, -(CH₂)₄-NH₂, -(CH₂)₅-NH₂ and the like.

 “Mono-alkylaminoalkyl” means -(alkyl)-NH(alkyl), wherein each alkyl is
independently an alkyl group defined above, including -CH₂-NH-CH₃, -CH₂-
NHCH₂CH₃, -CH₂-NH(CH₂)₂CH₃, -CH₂-NH(CH₂)₃CH₃, -CH₂-NH(CH₂)₄CH₃, -CH₂-
10 NH(CH₂)₅CH₃, -(CH₂)₂-NH-CH₃, and the like.

 “Di-alkylaminoalkyl” means -(alkyl)-N(alkyl)(alkyl), wherein each alkyl
is independently an alkyl group defined above, including -CH₂-N(CH₃)₂, -CH₂-
N(CH₂CH₃)₂, -CH₂-N((CH₂)₂CH₃)₂, -CH₂-N(CH₃)(CH₂CH₃), -(CH₂)₂-N(CH₃)₂, and the
like.

15 “Heteroaryl” means an aromatic heterocycle ring of 5- to 10 members and
having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing
at least 1 carbon atom, including both mono- and bicyclic ring systems. Representative
heteroaryls are triazolyl, tetrazolyl, oxadiazolyl, pyridyl, furyl, benzofuranyl, thiophenyl,
benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl,
20 benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl,
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl,
pyrimidyl, oxetanyl, azepinyl, piperazinyl, morpholinyl, dioxanyl, thietanyl and
oxazolyl.

 “Heteroarylalkyl” means -(alkyl)-(heteroaryl), wherein alkyl and
25 heteroaryl are defined above, including -CH₂-triazolyl, -CH₂-tetrazolyl, -CH₂-
oxadiazolyl, -CH₂-pyridyl, -CH₂-furyl, -CH₂-benzofuranyl, -CH₂-thiophenyl, -CH₂-
benzothiophenyl, -CH₂-quinolinyl, -CH₂-pyrrolyl, -CH₂-indolyl, -CH₂-oxazolyl, -CH₂-
benzoxazolyl, -CH₂-imidazolyl, -CH₂-benzimidazolyl, -CH₂-thiazolyl, -CH₂-
benzothiazolyl, -CH₂-isoxazolyl, -CH₂-pyrazolyl, -CH₂-isothiazolyl, -CH₂-pyridazinyl, -
30 CH₂-pyrimidinyl, -CH₂-pyrazinyl, -CH₂-triazinyl, -CH₂-cinnolinyl, -CH₂-phthalazinyl, -
CH₂-quinazolinyl, -CH₂-pyrimidyl, -CH₂-oxetanyl, -CH₂-azepinyl, -CH₂-piperazinyl, -
CH₂-morpholinyl, -CH₂-dioxanyl, -CH₂-thietanyl, -CH₂-oxazolyl, -(CH₂)₂-triazolyl, and
the like.

 “Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-
35 membered bicyclic, heterocyclic ring which is either saturated, unsaturated, and which

5 contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, and the nitrogen heteroatom can be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle can be attached via any heteroatom or carbon atom. Heterocycles include heteroaryls as defined
10 above. Representative heterocycles include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

15 “Heterocycle fused to phenyl” means a heterocycle, wherein heterocycle is defined as above, that is attached to a phenyl ring at two adjacent carbon atoms of the phenyl ring.

“Heterocycloalkyl” means -(alkyl)-(heterocycle), wherein alkyl and heterocycle are defined above, including -CH₂-morpholinyl, -CH₂-pyrrolidinonyl, -CH₂-pyrrolidinyl, -CH₂-piperidinyl, -CH₂-hydantoinyl, -CH₂-valerolactamyl, -CH₂-oxiranyl, -CH₂-oxetanyl, -CH₂-tetrahydrofuranyl, -CH₂-tetrahydropyranyl, -CH₂-tetrahydropyridinyl, -CH₂-tetrahydroprimidinyl, -CH₂-tetrahydrothiophenyl, -CH₂-tetrahydrothiopyranyl, -CH₂-tetrahydropyrimidinyl, -CH₂-tetrahydrothiophenyl, -CH₂-tetrahydrothiopyranyl, and the like.

25 The term “substituted” as used herein means any of the above groups (*i.e.*, aryl, arylalkyl, heterocycle and heterocycloalkyl) wherein at least one hydrogen atom of the moiety being substituted is replaced with a substituent. In one embodiment, each carbon atom of the group being substituted is substituted with no more than two substituents. In another embodiment, each carbon atom of the group being substituted is substituted with no more than one substituent. In the case of a keto substituent, two
30 hydrogen atoms are replaced with an oxygen which is attached to the carbon via a double bond. Substituents include halogen, hydroxyl, alkyl, haloalkyl, mono- or di-substituted aminoalkyl, alkyloxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, -NR_aR_b, -NR_aC(=O)R_b, -NR_aC(=O)NR_aR_b, -NR_aC(=O)OR_b, -NR_aSO₂R_b, -OR_a, -C(=O)R_a,
35 C(=O)OR_a, -C(=O)NR_aR_b, -OC(=O)R_a, -OC(=O)OR_a, -OC(=O)NR_aR_b, -NR_aSO₂R_b, or a

5 radical of the formula -Y-Z-R_a where Y is alkanediyl, or a direct bond, Z is -O-, -S-, -N(R_b)-, -C(=O)-, -C(=O)O-, -OC(=O)-, -N(R_b)C(=O)-, -C(=O)N(R_b)- or a direct bond, wherein R_a and R_b are the same or different and independently hydrogen, amino, alkyl, haloalkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or wherein R_a and R_b taken together with the nitrogen atom to which they are attached form a heterocycle.

10 “Haloalkyl” means alkyl, wherein alkyl is defined as above, having one or more hydrogen atoms replaced with halogen, wherein halogen is as defined above, including -CF₃, -CHF₂, -CH₂F, -CBr₃, -CHBr₂, -CH₂Br, -CCl₃, -CHCl₂, -CH₂Cl, -Cl₃, -CHI₂, -CH₂I, -CH₂-CF₃, -CH₂-CHF₂, -CH₂-CH₂F, -CH₂-CBr₃, -CH₂-CHBr₂, -CH₂-CH₂Br, -CH₂-CCl₃, -CH₂-CHCl₂, -CH₂-CH₂Cl, -CH₂-Cl₃, -CH₂-CHI₂, -CH₂-CH₂I, and

15 the like.

“Hydroxyalkyl” means alkyl, wherein alkyl is as defined above, having one or more hydrogen atoms replaced with hydroxy, including -CH₂OH, -CH₂CH₂OH, -(CH₂)₂CH₂OH, -(CH₂)₃CH₂OH, -(CH₂)₄CH₂OH, -(CH₂)₅CH₂OH, -CH(OH)-CH₃, -CH₂CH(OH)CH₃, and the like.

20 “Hydroxy” means -OH.

“Sulfonyl” means -SO₃H.

“Sulfonylalkyl” means -SO₂-(alkyl), wherein alkyl is defined above, including -SO₂-CH₃, -SO₂-CH₂CH₃, -SO₂-(CH₂)₂CH₃, -SO₂-(CH₂)₃CH₃, -SO₂-(CH₂)₄CH₃, -SO₂-(CH₂)₅CH₃, and the like.

25 “Sulfinylalkyl” means -SO-(alkyl), wherein alkyl is defined above, including -SO-CH₃, -SO-CH₂CH₃, -SO-(CH₂)₂CH₃, -SO-(CH₂)₃CH₃, -SO-(CH₂)₄CH₃, -SO-(CH₂)₅CH₃, and the like.

“Sulfonamidoalkyl” means -NHSO₂-(alkyl), wherein alkyl is defined above, including -NHSO₂-CH₃, -NHSO₂-CH₂CH₃, -NHSO₂-(CH₂)₂CH₃, -NHSO₂-(CH₂)₃CH₃, -NHSO₂-(CH₂)₄CH₃, -NHSO₂-(CH₂)₅CH₃, and the like.

30 “Thioalkyl” means -S-(alkyl), wherein alkyl is defined above, including -S-CH₃, -S-CH₂CH₃, -S-(CH₂)₂CH₃, -S-(CH₂)₃CH₃, -S-(CH₂)₄CH₃, -S-(CH₂)₅CH₃, and the like.

As used herein, the term “JNK Inhibitor” encompasses, but is not limited to, compounds disclosed herein. Without being limited by theory, specific JNK

35

5 Inhibitors capable of inhibiting the activity of JNK *in vitro* or *in vivo*. The JNK Inhibitor can be in the form of a pharmaceutically acceptable salt, free base, solvate, hydrate, stereoisomer, clathrate or prodrug thereof. Such inhibitory activity can be determined by an assay or animal model well-known in the art including those set forth in Section 5. In one embodiment, the JNK Inhibitor is a compound of structure (I)-(III).

10 “JNK” means a protein or an isoform thereof expressed by a JNK 1, JNK 2, or JNK 3 gene (Gupta, S., Barrett, T., Whitmarsh, A.J., Cavanagh, J., Sluss, H.K., Derijard, B. and Davis, R.J. *The EMBO J.* 15:2760-2770 (1996)).

As used herein, the phrase “an effective amount” when used in connection with a JNK Inhibitor means an amount of the JNK Inhibitor that is useful for for treating, preventing, managing and/or modifying pain.

15 As used herein, the phrase “an effective amount” when used in connection with another therapeutic or prophylactic agent means an amount of the other therapeutic or prophylactic agent that is useful for for treating, preventing, managing and/or modifying pain when administered while the JNK Inhibitor exerts its therapeutic or prophylactic activity.

20 As used herein, the term “pharmaceutically acceptable salt(s)” refers to a salt prepared from a pharmaceutically acceptable non-toxic acid or base including an inorganic acid and base and an organic acid and base. Suitable pharmaceutically acceptable base addition salts of the JNK Inhibitor include, but are not limited to metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.

25 Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid. Specific non-toxic acids include hydrochloric, hydrobromic,

30 phosphoric, sulfuric, and methanesulfonic acids. Examples of specific salts thus include

35

5 hydrochloride and mesylate salts. Others are well-known in the art, see for example, *Remington's Pharmaceutical Sciences*, 18th eds., Mack Publishing, Easton PA (1990) or *Remington: The Science and Practice of Pharmacy*, 19th eds., Mack Publishing, Easton PA (1995).

As used herein and unless otherwise indicated, the term "polymorph"
10 means a particular crystalline arrangement of the JNK Inhibitor. Polymorphs can be obtained through the use of different work-up conditions and/or solvents. In particular, polymorphs can be prepared by recrystallization of a JNK Inhibitor in a particular solvent.

As used herein and unless otherwise indicated, the term "prodrug" means
15 a JNK Inhibitor derivative that can hydrolyze, oxidize, or otherwise react under biological conditions (*in vitro* or *in vivo*) to provide an active compound, particularly a JNK Inhibitor. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a JNK Inhibitor that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates,
20 biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Preferably, prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by *Burger's*
25 *Medicinal Chemistry and Drug Discovery* 6th ed. (Donald J. Abraham *ed.*, 2001, Wiley) and *Design and Application of Prodrugs* (H. Bundgaard *ed.*, 1985, Harwood Academic Publishers Gmhf).

As used herein and unless otherwise indicated, the term "optically pure" or "stereomerically pure" means one stereoisomer of a compound is substantially free of
30 other stereoisomers of that compound. For example, a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure a compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the
35 compound and less than about 20% by weight of other stereoisomers of the compound,

5 more preferably greater than about 90% by weight of one stereoisomer of the compound
and less than about 10% by weight of the other stereoisomers of the compound, even
more preferably greater than about 95% by weight of one stereoisomer of the compound
and less than about 5% by weight of the other stereoisomers of the compound, and most
preferably greater than about 97% by weight of one stereoisomer of the compound and
10 less than about 3% by weight of the other stereoisomers of the compound.

As used herein, the terms “complex regional pain syndrome,” “CRPS”
and “CRPS and related syndromes” mean a chronic pain disorder characterized by one or
more of the following: pain, whether spontaneous or evoked, including allodynia
(painful response to a stimulus that is not usually painful) and hyperalgesia (exaggerated
15 response to a stimulus that is usually only mildly painful); pain that is disproportionate to
the inciting event (*e.g.*, years of severe pain after an ankle sprain); regional pain that is
not limited to a single peripheral nerve distribution; and autonomic dysregulation (*e.g.*,
edema, alteration in blood flow and hyperhidrosis) associated with trophic skin changes
(hair and nail growth abnormalities and cutaneous ulceration). Unless otherwise
20 indicated, the terms “complex regional pain syndrome” and “CRPS” include: type I,
encompassing the condition known as reflex sympathetic dystrophy (RSD), which
occurs after an initial noxious event other than a nerve injury; type II, encompassing the
condition known as causalgia, which occurs after nerve injury; acute stage (usually
hyperthermic phase of 2-3 months); dystrophic phase (showing vasomotor instability for
25 several months); atrophic phase (usually cold extremity with atrophic changes); reflex
neurovascular dystrophy; reflex dystrophy; sympathetic maintained pain syndrome;
Sudeck atrophy of bone; algoneurodystrophy; shoulder hand syndrome; post-traumatic
dystrophy; trigeminal neuralgia; post herpetic neuralgia; cancer related pain; phantom
limb pain; fibromyalgia; chronic fatigue syndrome; radiculopathy; and other painful
30 neuropathic conditions, *e.g.*, diabetic neuropathy, luetic neuropathy, painful neuropathy
induced iatrogenically by drugs such as vincristine, velcade or thalidomide.

As used herein, unless otherwise specified, the term “treating pain” refers
to the administration of a JNK Inhibitor, optionally in combination with another active
agent or other therapy, after the onset of a symptom of pain, whereas “preventing
35 pain” refers to the administration of a JNK Inhibitor, optionally in combination with


5 another active agent or other therapy, prior to the onset of a symptom of pain,
particularly to patients at risk of experiencing pain. Examples of patients at risk of
experiencing pain include, but are not limited to, those who have incidents of trauma,
neurologic disorder, genetic disorder, myocardial infarction, surgery, musculoskeletal
disorder or malignancy. Patients with familial history of pain are also preferred
10 candidates for preventive regimens. As used herein, unless otherwise indicated, the term
“managing pain” encompasses preventing the recurrence of pain in a patient who has
suffered from pain, and/or lengthening the time that a patient who has suffered from pain
remains in remission. As used herein, unless otherwise specified, the term “modifying
pain” means changing the way that a patient responds to pain. In one embodiment,
15 “modifying pain” means bringing a patient’s pain threshold from an elevated level (*i.e.*, a
level at which a patient experiences greater than normal pain in response to a particular
stimulus) back to a normal level. In another embodiment, “modifying pain” means
reducing a patient’s pain response to a stimulus of a particular intensity. In another
embodiment, modifying pain” means increasing a patient’s pain threshold relative to the
20 patient’s pain threshold prior to the administration of an effective amount of a JNK
Inhibitor.

4. DETAILED DESCRIPTION OF THE INVENTION

4.1 ILLUSTRATIVE JNK INHIBITORS

As mentioned above, the present invention is directed to methods useful
25 for treating, preventing, managing and/or modifying pain, comprising administering an
effective amount of a JNK Inhibitor to a patient in need thereof. Illustrative JNK
Inhibitors are set forth below.

In one embodiment, the JNK Inhibitor has the following structure (I):



30 wherein:

5 A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv$
 $C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3 ;

10 R_2 is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$,
 $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$,
 $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$,
 $-(CH_2)_bSO_aR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently
15 selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$,
20 $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$,
 $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, each being optionally substituted with one to four substituents independently selected from R_3 , or R_4
25 is halogen or hydroxy;

R_5 , R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, wherein each of R_5 , R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3 ; and

30 R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8 , R_9 , and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3 .

5 In one embodiment, -A-R₁ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR₈C(=O)R₉, -C(=O)NR₈R₉, and -O(CH₂)_bNR₈R₉, wherein *b* is 2 or 3 and wherein R₈ and R₉ are defined above.

In another embodiment, R₂ is -R₄, -(CH₂)_bC(=O)R₅, -(CH₂)_bC(=O)OR₅,
10 -(CH₂)_bC(=O)NR₅R₆, -(CH₂)_bC(=O)NR₅(CH₂)_cC(=O)R₆, -(CH₂)_bNR₅C(=O)R₆,
-(CH₂)_bNR₅C(=O)NR₆R₇, -(CH₂)_bNR₅R₆, -(CH₂)_bOR₅, -(CH₂)_bSO_dR₅ or
-(CH₂)_bSO₂NR₅R₆, and *b* is an integer ranging from 0-4.

In another embodiment, R₂ is -(CH₂)_bC(=O)NR₅R₆, -(CH₂)_bNR₅C(=O)R₆,
3-triazolyl or 5-tetrazolyl, wherein *b* is 0 and wherein R₈ and R₉ are defined above.

15 In another embodiment, R₂ is 3-triazolyl or 5-tetrazolyl.

In another embodiment:

(a) -A-R₁ is phenyl, optionally substituted with one to four substituents
independently selected from halogen, alkoxy, -NR₈C(=O)R₉, -C(=O)NR₈R₉,
and -O(CH₂)_bNR₈R₉, wherein *b* is 2 or 3; and
20 (b) R₂ is -(CH₂)_bC(=O)NR₅R₆, -(CH₂)_bNR₅C(=O)R₆, 3-triazolyl or 5-
tetrazolyl, wherein *b* is 0 and wherein R₈ and R₉ are defined above.

In another embodiment:

(a) -A-R₁ is phenyl, optionally substituted with one to four substituents
independently selected from halogen, alkoxy, -NR₈C(=O)R₉, -C(=O)NR₈R₉, and
25 -O(CH₂)_bNR₈R₉, wherein *b* is 2 or 3; and



(b) R₂ is 3-triazolyl or 5-tetrazolyl.

In another embodiment, R₂ is R₄, and R₄ is 3-triazolyl, optionally
substituted at its 5-position with:



(a) a C₁-C₄ straight or branched chain alkyl group optionally substituted
30 with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
(b) a 2-pyrrolidinyl group.

In another embodiment, R₂ is R₄, and R₄ is 3-triazolyl, optionally
substituted at its 5-position with: methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-
hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-
35 pyrrolidinylmethyl or 2-pyrrolidinyl.


5 In another embodiment, the compounds of structure (I) have structure (IA) when A is a direct bond, or have structure (IB) when A is $-(CH_2)_a-$:




In other embodiments, the compounds of structure (I) have structure (IC) when A is a $-(CH_2)_bCH=CH(CH_2)_c-$, and have structure (ID) when A is $-(CH_2)_bC\equiv C(CH_2)_c-$ 10 $C(CH_2)_c-$:



In further embodiments of this invention, R_1 of structure (I) is aryl or substituted aryl, such as phenyl or substituted phenyl as represented by the following structure (IE):



15 In another embodiment, R_2 of structure (I) is $-(CH_2)_bNR_4(C=O)R_5$. In one aspect of this embodiment, $b = 0$ and the compounds have the following structure (IF):




5 Representative R₂ groups of the compounds of structure (I) include alkyl
(such as methyl and ethyl), halo (such as chloro and fluoro), haloalkyl (such as
trifluoromethyl), hydroxy, alkoxy (such as methoxy and ethoxy), amino, arylalkyloxy
(such as benzyloxy), mono- or di-alkylamine (such as -NHCH₃, -N(CH₃)₂ and -
NHCH₂CH₃), -NHC(=O)R₄ wherein R₆ is a substituted or unsubstituted phenyl or
10 heteroaryl (such as phenyl or heteroaryl substituted with hydroxy, carboxy, amino, ester,
alkoxy, alkyl, aryl, haloalkyl, halo, -CONH₂ and -CONH alkyl), -NH(heteroarylalkyl)
(such as -NHCH₂(3-pyridyl), -NHCH₂(4-pyridyl), heteroaryl (such as pyrazolo, triazolo
and tetrazolo), -C(=O)NHR₆ wherein R₆ is hydrogen, alkyl, or as defined above (such as
-C(=O)NH₂, -C(=O)NHCH₃, -C(=O)NH(H-carboxyphenyl), -C(=O)N(CH₃)₂),
15 arylalkenyl (such as phenylvinyl, 3-nitrophenylvinyl, 4-carboxyphenylvinyl),
heteroarylalkenyl (such as 2-pyridylvinyl, 4-pyridylvinyl).

Representative R₃ groups of the compounds of structure (I) include
halogen (such as chloro and fluoro), alkyl (such as methyl, ethyl and isopropyl),
haloalkyl (such as trifluoromethyl), hydroxy, alkoxy (such as methoxy, ethoxy, n-
20 propyloxy and isobutyloxy), amino, mono- or di-alkylamino (such as dimethylamine),
aryl (such as phenyl), carboxy, nitro, cyano, sulfinylalkyl (such as methylsulfinyl),
sulfonylalkyl (such as methylsulfonyl), sulfonamidoalkyl (such as -NHSO₂CH₃),
-NR₈C(=O)(CH₂)_bOR₉ (such as NHC(=O)CH₂OCH₃), NHC(=O)R₉ (such as
-NHC(=O)CH₃, -NHC(=O)CH₂C₆H₅, -NHC(=O)(2-furanyl)), and -O(CH₂)_bNR₈R₉ (such
25 as -O(CH₂)₂N(CH₃)₂).


The compounds of structure (I) can be made using organic synthesis
techniques known to those skilled in the art, as well as by the methods described in
International Publication No. WO 02/10137 (particularly in Examples 1-430, at page 35,
line 1 to page 396, line 12), published February 7, 2002, which is incorporated herein by
30 reference in its entirety. Further, specific examples of these compounds are found in this
publication.

Illustrative examples of JNK Inhibitors of structure (I) are:


5




3-(4-Fluoro-phenyl)-5-(1H-[1,2,4]triazol-3-yl)-1H-indazole;




3-[3-(2-Piperidin-1-yl-ethoxy)-phenyl]-5-(1H-[1,2,4]triazol-3-yl)-1H-indazole ;



3-(4-Fluoro-phenyl)-1H-indazole-5-carboxylic acid (3-morpholin-4-yl-propyl)-amide ;




3-[3-(3-Piperidin-1-yl-propionylamino)-phenyl]-1H-indazole-5-carboxylic acid amide ;




3-Benzo[1,3]dioxol-5-yl-5-(2H-tetrazol-5-yl)-1H-indazole ;


5




3-(4-Fluoro-phenyl)-5-(5-methyl-[1,3,4]oxadiazol-2-yl)-1*H*-indazole ;



N-tert-Butyl-3-[5-(1*H*-[1,2,4]triazol-3-yl)-1*H*-indazol-3-yl]-benzamide ;




3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-5-(1*H*-[1,2,4]triazol-3-yl)-1*H*-indazole ;




Dimethyl-(2-{4-[5-(1*H*-[1,2,4]triazol-3-yl)-1*H*-indazol-3-yl]-phenoxy}-ethyl)-amine ;


5




5-[5-(1,1-Dimethyl-propyl)-1H-[1,2,4]triazol-3-yl]-3-(4-fluoro-phenyl)-1H-indazole ;



3-(4-Fluoro-phenyl)-5-(5-pyrrolidin-1-ylmethyl-1H-[1,2,4]triazol-3-yl)-1H-indazole ;



3-(6-Methoxy-naphthalen-2-yl)-5-(5-pyrrolidin-1-ylmethyl-1H-[1,2,4]triazol-3-yl)-1H-indazole ;




3-(4-Fluoro-phenyl)-1H-indazole-5-carboxylic acid amide ;

and pharmaceutically acceptable salts thereof.

10

In another embodiment, the JNK Inhibitor has the following structure

(II):



(II)

wherein:

R_1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R_7 ;

R_2 is hydrogen;

10 R_3 is hydrogen or lower alkyl;

R_4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;

R_5 and R_6 are the same or different and independently - R_8 ,

15 $-(CH_2)_aC(=O)R_9$, $-(CH_2)_aC(=O)OR_9$, $-(CH_2)_aC(=O)NR_9R_{10}$,
 $-(CH_2)_aC(=O)NR_9(CH_2)_bC(=O)R_{10}$, $-(CH_2)_aNR_9C(=O)R_{10}$, $(CH_2)_aNR_{11}C(=O)NR_9R_{10}$,
 $-(CH_2)_aNR_9R_{10}$, $-(CH_2)_aOR_9$, $-(CH_2)_aSO_cR_9$ or $-(CH_2)_aSO_2NR_9R_{10}$;

or R_5 and R_6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

20 R_7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, substituted heterocycle, heterocycloalkyl, - $C(=O)OR_8$, - $OC(=O)R_8$, - $C(=O)NR_8R_9$, - $C(=O)NR_8OR_9$, - SO_cR_8 , - $SO_cNR_8R_9$, - $NR_8SO_cR_9$, - NR_8R_9 , - $NR_8C(=O)R_9$, - $NR_8C(=O)(CH_2)_bOR_9$, - $NR_8C(=O)(CH_2)_bR_9$,
 25 - $O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_8 , R_9 , R_{10} and R_{11} are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl;

or R_8 and R_9 taken together with the atom or atoms to which they are attached to form a heterocycle;

30 a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and

5 c is at each occurrence 0, 1 or 2.

In one embodiment, R_1 is a substituted or unsubstituted aryl or heteroaryl. When R_1 is substituted, it is substituted with one or more substituents defined below. In one embodiment, when substituted, R_1 is substituted with a halogen, $-SO_2R_8$ or $-SO_2R_8R_9$.

10 In another embodiment, R_1 is substituted or unsubstituted aryl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinoliny, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnoliny, phthalazinyl or quinazolinyl.


15 In another embodiment R_1 is substituted or unsubstituted aryl or heteroaryl. When R_1 is substituted, it is substituted with one or more substituents defined below. In one embodiment, when substituted, R_1 is substituted with a halogen, $-SO_2R_8$ or $-SO_2R_8R_9$.

In another embodiment, R_1 is substituted or unsubstituted aryl, preferably phenyl. When R_1 is a substituted aryl, the substituents are defined below. In one embodiment, when substituted, R_1 is substituted with a halogen, $-SO_2R_8$ or $-SO_2R_8R_9$.

In another embodiment, R_5 and R_6 , taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted nitrogen-containing non-aromatic heterocycle, in one embodiment, piperazinyl, piperidinyl or morpholinyl.

25 When R_5 and R_6 , taken together with the nitrogen atom to which they are attached form substituted piperazinyl, piperadinyl or morpholinyl, the piperazinyl, piperadinyl or morpholinyl is substituted with one or more substituents defined below. In one embodiment, when substituted, the substituent is alkyl, amino, alkylamino, alkoxyalkyl, acyl, pyrrolidinyl or piperidinyl.


30 In one embodiment, R_3 is hydrogen and R_4 is not present, and the JNK Inhibitor has the following structure (IIA):



(IIA)

and pharmaceutically acceptable salts thereof.


In a more specific embodiment, R₁ is phenyl optionally substituted with R₇, and having the following structure (IIB):



(IIB)

and pharmaceutically acceptable salts thereof.

In still a further embodiment, R₇ is at the para position of the phenyl group relative to the pyrimidine, as represented by the following structure (IIC):




(IIC)

and pharmaceutically acceptable salts thereof.


The JNK Inhibitors of structure (II) can be made using organic synthesis techniques known to those skilled in the art, as well as by the methods described in International Publication No. WO 02/46170 (particularly Examples 1-27 at page 23, line 5 to page 183, line 25), published June 13, 2002, which is hereby incorporated by reference in its entirety. Further, specific examples of these compounds are found in the publication.

Illustrative examples of JNK Inhibitors of structure (II) are:


5




4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-benzamide ;




4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-*N,N*-dimethylbenzamide ;



4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-*N*-(3-piperidin-1-yl-propyl)-benzamide ;




{4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-phenyl}-piperazin-1-yl-methanone ;




1-(4-{4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-benzoyl}-piperazin-1-yl)-ethanone ;

5



1-[4-(4-{4-[4-(3-Hydroxy-propylsulfanyl)-phenyl]-pyrimidin-2-ylamino}-benzoyl)-piperazin-1-yl]-ethanone ;




{4-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-phenyl}-(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone ;

and pharmaceutically acceptable salts thereof.


In another embodiment, the JNK Inhibitor has the following structure

10 (III):



(III)

5 wherein R_0 is -O-, -S-, -S(O)-, -S(O)₂-, NH or -CH₂-;
 the compound of structure (III) being: (i) unsubstituted, (ii)
 10 monosubstituted and having a first substituent, or (iii) disubstituted and having a first
 substituent and a second substituent;
 the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10
 10 position, wherein the first and second substituent, when present, are independently alkyl,
 hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxy, alkoxyalkyl,
 aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl,
 alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group
 15 represented by structure (a), (b), (c), (d), (e), or (f):




 wherein R_3 and R_4 are taken together and represent alkylidene or a
 heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl,
 20 cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl,
 mono-alkylaminoalkyl, or di-alkylaminoalkyl; and
 R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy,
 alkoxyalkyl, alkoxyalkoxyalkyl, amino, mono-alkylamino, di-alkylamino, arylamino,
 arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-
 25 alkylaminoalkyl, or di-alkylaminoalkyl.

5

In another embodiment, the JNK Inhibitor has the following structure


(IIIA):




2H-Dibenzo[cd,g]indol-6-one
(IIIA)

being: (i) unsubstituted, (ii) monosubstituted and having a first
10 substituent, or (iii) disubstituted and having a first substituent and a second substituent;
the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10
position;


wherein the first and second substituent, when present, are independently
alkyl, hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxy, carbonyl,
15 alkoxy, aryl, aryloxy, arylalkoxy, arylalkyl, cycloalkylalkoxy, cycloalkyl,
alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono- alkylaminoalkoxy, di-
alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):




(a)




(b)




(c)



(d)



(e)



(f)

wherein R₃ and R₄ are taken together and represent alkylidene or a
20 heteroatom-containing cyclic alkylidene or R₃ and R₄ are independently hydrogen, alkyl,

5 cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxyalkylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-
10 alkylaminoalkyl, or di-alkylaminoalkyl.

A subclass of the compounds of structure (IIIA) is that wherein the first or second substituent is present at the 5, 7, or 9 position. In one embodiment, the first or second substituent is present at the 5 or 7 position.


A second subclass of compounds of structure (IIIA) is that wherein the
15 first or second substituent is present at the 5, 7, or 9 position;

the first or second substituent is independently alkoxy, aryloxy, aminoalkyl, mono-alkylaminoalkyl, di-alkylaminoalkyl, or a group represented by the structure (a), (c), (d), (e), or (f);

R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl,
20 or cycloalkylalkyl; and

R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl.

In another embodiment, the JNK Inhibitor has the following structure (IIIB):




2-Oxo-2H-21⁴-anthra[9,1-cd]
isothiazol-6-one
(IIIB)

25 being (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (ii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position;

5 wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b) (c), (d), (e), or (f):



10

 wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

15 R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.


20 A subclass of the compounds of structure (IIIB) is that wherein the first or second substituent is present at the 5, 7, or 9 position. In one embodiment, the first or second substituent is present at the 5 or 7 position.

 A second subclass of the compounds of structure (IIIB) is that wherein the first or second substituent is independently alkoxy, aryloxy, or a group represented by the structure (a), (c), (d), (e), or (f);

5 R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl; and

R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl.

In another embodiment, the JNK Inhibitor has the following structure (IIIC):




2-Oxa-1-aza-accanthrylen-6-one
(IIIC)

10

being (i) monosubstituted and having a first substituent or (ii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position;

15 wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c) (d), (e), or (f):



5

wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl,
 10 mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxyalkylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.


15 A subclass of the compounds of structure (IIIC) is that wherein the first or second substituent is present at the 5, 7, or 9 position. In one embodiment, the first or second substituent is present at the 5 or 7 position.

A second subclass of the compounds of structure (IIIC) is that wherein the first or second substituent is independently alkoxy, aryloxy, aminoalkyl, mono-alkylaminoalkyl, di-alkylaminoalkyl, or a group represented by the structure (a), (c), (d),
 20 (e), or (f);

R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl.

25 In another embodiment, the JNK Inhibitor has the following structure (IIID):









2,2-Dioxo-2H-21⁶-anthra
[9,1-cd]isothiazol-6-one
(IIID)

5

being (i) monosubstituted and having a first substituent present at the 5, 7, or 9 position, (ii) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 7 position, (iii) disubstituted and having a first substituent present at the 5 position and a second substituent present at the 9 position, or
10 (iv) disubstituted and having a first substituent present at the 7 position and a second substituent present at the 9 position;

wherein the first and second substituent, when present, are independently alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy,
15 alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):



5 wherein R₃ and R₄ are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

 R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, 10 alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.

 A subclass of the compounds of structure (IIID) is that wherein the first or second substituent is present at the 5 or 7 position.


15 A second subclass of the compounds of structure (IIID) is that wherein the first or second substituent is independently alkyl, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (c), (d), (e), or (f).

20 Another subclass of the compounds of structure (IIID) is that wherein the first and second substituent are independently alkoxy, aryloxy, or a group represented by the structure (a), (c), (d), (e), or (f);

 R₃ and R₄ are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, or cycloalkylalkyl; and

25 R₅ is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, alkoxycarbonyl, or cycloalkylalkyl.


 In another embodiment, the JNK Inhibitor has the following structure (IIIE):



Anthra[9,1-*cd*]isothiazol-6-one
(IIIE)

5 being (i) monosubstituted and having a first substituent present at the 5, 7,
or 9 position, (ii) disubstituted and having a first substituent present at the 5 position and
a second substituent present at the 9 position, (iii) disubstituted and having a first
substituent present at the 7 position and a second substituent present at the 9 position, or
10 (iv) disubstituted and having a first substituent present at the 5 position and a second
substituent present at the 7 position;

wherein the first and second substituent, when present, are independently
alkyl, halogen, hydroxy, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl,
alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy,
alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy,
15 or a group represented by structure (a), (b), (c), (d), (e), or (f):



wherein R_3 and R_4 are taken together and represent alkylidene or a
heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl,
20 cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl,
mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy,
alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino,
arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-
25 alkylaminoalkyl, or di-alkylaminoalkyl.


5 A subclass of the compounds of structure (IIIE) is that wherein the first or second substituent is present at the 5 or 7 position.

A second subclass of the compounds of structure (IIIE) is that wherein the compound of structure (IIIE) is disubstituted and at least one of the substituents is a group represented by the structure (d) or (f).

10 Another subclass of the compounds of structure (IIIE) is that wherein the compounds are monosubstituted. Yet another subclass of compounds is that wherein the compounds are monosubstituted at the 5 or 7 position with a group represented by the structure (e) or (f).

In another embodiment, the JNK Inhibitor has the following structure

15 (IIIF):




2*H*-Dibenzo[*cd,g*]indazol-6-one
(IIIF)

being (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (iii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position;

20 wherein the first and second substituent, when present, are independently alkyl, hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono- alkylaminoalkoxy, di-
25 alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):



wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and


R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.

In one embodiment, the compound of structure (IIIF), or a pharmaceutically acceptable salt thereof is unsubstituted at the 3, 4, 5, 7, 8, 9, or 10 position.


The JNK Inhibitors of structure (III) can be made using organic synthesis techniques known to those skilled in the art, as well as by the methods described in International Publication No. WO 01/12609 (particularly Examples 1-7 at page 24, line 6 to page 49, line 16), published February 22, 2001, as well as International Publication No. WO 02/066450 (particularly compounds AA-HG at pages 59-108), published August 29, 2002, each of which is hereby incorporated by reference in its entirety. Further, specific examples of these compounds can be found in the publications.

Illustrative examples of JNK Inhibitors of structure (III) are:


5




2H-Dibenzo[*cd,g*]
indazol-6-one ;



7-Chloro-*2H*-dibenzo[*cd,g*]
indazol-6-one ;




5-Dimethylamino-*2H*-
dibenzo[*cd,g*]indazol-6-one;




7-Benzoyloxy-*2H*-dibenzo[*cd,g*]indazol-
6-one ;


5




N-(6-Oxo-2,6-dihydro-dibenzo[*cd,g*]indazol-5-yl)-acetamide ;




5-(2-Piperidin-1-yl-ethylamino)-2*H*-dibenzo[*cd,g*]indazol-6-one ;




5-Amino-anthra[9,1-*cd*]isothiazol-6-one ;



N-(6-Oxo-6*H*-anthra[9,1-*cd*]isothiazol-5-yl)-benzamide ;



7-Dimethylamino-anthra[9,1-
cd]isothiazol-6-one ;



2-Oxa-1-aza-aceanthrylen-6-one;

and pharmaceutically acceptable salts thereof.

Other JNK Inhibitors that are useful in the present methods include, but are not limited to, those disclosed in International Publication No. WO 00/39101, (particularly at page 2, line 10 to page 6, line 12); International Publication No. WO 01/14375 (particularly at page 2, line 4 to page 4, line 4); International Publication No. WO 00/56738 (particularly at page 3, line 25 to page 6, line 13); International Publication No. WO 01/27089 (particularly at page 3, line 7 to page 5, line 29); International Publication No. WO 00/12468 (particularly at page 2, line 10 to page 4, line 14); European Patent Publication 1 110 957 (particularly at page 19, line 52 to page 21, line 9); International Publication No. WO 00/75118 (particularly at page 8, line 10 to page 11, line 26); International Publication No. WO 01/12621 (particularly at page 8, line 10 to page 10, line 7); International Publication No. WO 00/64872 (particularly at page 9, line 1 to page, 106, line 2); International Publication No. WO 01/23378 (particularly at page 90, line 1 to page 91, line 11); International Publication No. WO 02/16359 (particularly at page 163, line 1 to page 164, line 25); United States Patent No. 6,288,089 (particularly at column 22, line 25 to column 25, line 35); United States Patent No. 6,307,056 (particularly at column 63, line 29 to column 66, line 12); International Publication No. WO 00/35921 (particularly at page 23, line 5 to page 26, line 14);

5 International Publication No. WO 01/91749 (particularly at page 29, lines 1-22);
International Publication No. WO 01/56993 (particularly in at page 43 to page 45); and
International Publication No. WO 01/58448 (particularly in at page 39), each of which is
incorporated by reference herein in its entirety.

Pharmaceutical compositions including dosage forms of the invention,
10 which comprise an effective amount of a JNK Inhibitor can be used in the methods of the
invention.

4.2 METHODS OF USE

This invention is based, in part, on the belief that a JNK Inhibitor can
work alone or in combination with another active agent or physical therapy to effectively
15 treat, prevent, manage and/or modify varying types and severities of pain. Without being
limited by theory, compounds of the invention can, but do not necessarily, act as
analgesics. In particular, because a JNK Inhibitor can dramatically affect the production
of cytokines (*e.g.*, TNF- α), it is believed that they can function as “antihyperalgesics”
and/or “neuromodulators” by restoring the baseline or normal pain threshold of the
20 injured patient to which they are administered. Thus, a JNK Inhibitor can act differently
than an analgesic, which typically diminishes the response induced by stimulus, by
instead altering the patient’s ability to withstand that response either by suppressing the
suffering associated with the pain or directly reducing the responsiveness of the
nociceptors. For this reason, it is believed that a JNK Inhibitor can be used to treat,
25 prevent, manage and/or modify not only nociceptive pain, but other types of pain (*e.g.*,
neuropathic pain) with substantially different etiologies. Moreover, because of the
unique mechanism by which a JNK Inhibitor is believed to act, it is believed that a JNK
Inhibitor can relieve or reduce pain without incurring adverse effects (*e.g.*, narcotic
effects) typical of some analgesics (*e.g.*, opioids), even when administered systemically.

30 Methods of this invention encompass methods for treating, preventing,
managing and/or modifying various types of pain and related syndromes, comprising
administering an effective amount of a JNK Inhibitor to a patient in need thereof.

In one embodiment, the invention relates to a method for treating,
preventing, managing and/or modifying nociceptive pain, comprising administering an
35 effective amount of a JNK Inhibitor to a patient in need thereof. In certain embodiments,

5 the nociceptive pain results from physical trauma (*e.g.*, a cut or contusion of the skin; or a chemical or thermal burn), osteoarthritis, rheumatoid arthritis or tendonitis. In another embodiment, the nociceptive pain is myofascial pain.

In another embodiment, the invention relates to a method for treating, preventing, managing and/or modifying neuropathic pain, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. In certain embodiments, the neuropathic pain is associated with stroke, diabetic neuropathy, luetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, fibromyalgia, or painful neuropathy induced iatrogenically by drugs such as vincristine, velcade or thalidomide.

In another embodiment, the invention relates to a method for treating, preventing, managing and/or modifying mixed pain (*i.e.*, pain with both nociceptive and neuropathic components), comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof.

In another embodiment, the invention relates to a method for treating, preventing, managing and/or modifying visceral pain; headache pain (*e.g.*, migraine headache pain); mixed pain (*i.e.*, chronic pain having nociceptive and neuropathic components); CRPS; CRPS type I; CRPS type II; RSD; reflex neurovascular dystrophy; reflex dystrophy; sympathetically maintained pain syndrome; causalgia; Sudeck atrophy of bone; algoneurodystrophy; shoulder hand syndrome; post-traumatic dystrophy; autonomic dysfunction; cancer-related pain; phantom limb pain; fibromyalgia; myofascial pain; chronic fatigue syndrome; post-operative pain; spinal cord injury pain; central post-stroke pain; radiculopathy; sensitivity to temperature, light touch or color change to the skin (allodynia); pain from hyperthermic or hypothermic conditions; and other painful conditions (*e.g.*, diabetic neuropathy, luetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, or painful neuropathy induced iatrogenically by drugs such as vincristine, velcade or thalidomide), comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof.

In another embodiment, the invention relates to a method for treating, preventing, managing and/or modifying pain associated with a cytokine, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. In one embodiment, inhibiting cytokine activity or cytokine production results in the treatment,

5 prevention, management and/or modification of the pain. In another embodiment, the cytokine is TNF- α . In another embodiment, the pain associated with a cytokine is nociceptive pain. In another embodiment, the pain associated with a cytokine is neuropathic pain.

In another embodiment, the invention relates to a method for treating,
10 preventing, managing and/or modifying pain associated with a mitogen-activated protein kinase (MAPK), comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. In one embodiment, the MAPK is JNK (*e.g.*, JNK1, JNK2 or JNK3). In another embodiment, the MAPK is an extracellular signal-regulated kinase (ERK) (*e.g.*, ERK1 or ERK2). In another embodiment, the MAPK is p38.

15 In another embodiment, the invention relates to a method for treating, preventing, managing and/or modifying pain associated with inflammation, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof.

In another embodiment, the invention relates to a method of treating, preventing, managing and/or modifying pain associated with surgery, in one embodiment
20 planned surgery (*i.e.*, planned trauma), comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. In this embodiment, the JNK Inhibitor can be administered before, during and/or after the planned surgery. In a particular embodiment, the patient is administered about 5 to about 25 mg/day of a JNK Inhibitor from 1-21 days prior to the planned surgery and/or about 5 to about 25 mg/day of a JNK
25 Inhibitor from 1-21 days after the planned surgery. In another embodiment, the patient is administered about 10 mg/day of a JNK Inhibitor from 1-21 days prior to the planned surgery and/or about 10 mg/day of a JNK Inhibitor from 1-21 days after the planned surgery.

In a further embodiment, the invention relates to methods for treating a
30 patient who has been previously treated for pain (in particular, a patient who was non-responsive to standard pain therapy), as well as a patient who has not previously been treated for pain, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. Because a patient experiencing pain can have heterogenous clinical manifestations and varying clinical outcomes, the treatment given to a patient
35 can vary, depending on his/her prognosis. The skilled clinician will be able to readily

5 determine without undue experimentation specific secondary agents, types of surgery, or types of physical therapy that can be effectively used to treat an individual patient.

In a yet a further embodiment, the invention relates to methods for managing the development and duration of pain, comprising administering to a patient in need of such management an effective amount of a JNK Inhibitor.

10 **4.2.1 Combination Therapy With A Second Active Agent**

The invention further relates to methods for treating, preventing, managing and/or modifying pain, comprising administering a JNK Inhibitor in combination with a second active agent, such as a prophylactic or therapeutic agent, to a patient in need thereof.

15 Examples of second active agents include, but are not limited to, conventional therapeutics used to treat, prevent, manage and/or modify pain, including, but not limited to, antidepressants, anticonvulsants, antihypertensives, anxiolytics, calcium channel blockers, muscle relaxants, non-narcotic analgesics, opioid analgesics, anti-inflammatories, cox-2 inhibitors, alpha-adrenergic receptor agonists or antagonists, ketamine, anesthetics, immunomodulatory agents, immunosuppressive agents, corticosteroids, hyperbaric oxygen, anticonvulsants, NMDA antagonists, IMiDs[®] and SelCIDs[®] (Celgene Corporation, New Jersey) (e.g., those disclosed in U.S. patent nos. 6,075,041; 5,877,200; 5,698,579; 5,703,098; 6,429,221; 5,736,570; 5,658,940; 5,728,845; 5,728,844; 6,262,101; 6,020,358; 5,929,117; 6,326,388; 6,281,230; 20 5,635,517; 5,798,368; 6,395,754; 5,955,476; 6,403,613; 6,380,239; and 6,458,810, each of which is incorporated herein by reference), or a combination thereof, and other therapeutics found, for example, in the *Physician's Desk Reference* 2003.

The specific amount of the second active agent will depend on the specific agent used, the type of pain being treated or managed, the severity and stage of pain, and the amount(s) of a JNK Inhibitor and any optional additional active agents 30 concurrently administered to the patient. In a particular embodiment, the second active agent is salicyclic acid acetate, celcoxib, enbrel, thalidomide, an IMiD[®], a SelCID[®], gabapentin, phenytoin, carbamazepine, valproic acid, morphine sulfate, hydromorphone, prednisone, griseofulvin, penthonium, alendronate, dyphenhydramide, guanethidine, 35 ketorolac, thyrocalcitonin, dimethylsulfoxide, clonidine, bretylium, ketanserin, reserpine,

5 droperidol, atropine, phentolamine, bupivacaine, lidocaine, acetaminophen, nortriptyline, amitriptyline, imipramine, doxepin, clomipramine, fluoxetine, sertraline, nefazodone, venlafaxine, trazodone, bupropion, mexiletine, nifedipine, propranolol, tramadol, lamotrigine, ziconotide, ketamine, dextromethorphan, benzodiazepines, baclofen, tizanidine, phenoxybenzamine or a combination thereof, or a pharmaceutically
10 acceptable salt, solvate, hydrate, stereoisomer, clathrate, prodrug or pharmacologically active metabolite thereof.

Hydromorphone is preferably administered in an initial dose of about 2 mg orally, or about 1 mg intravenously to manage moderate to severe pain. *See, e.g., Physicians' Desk Reference*, 441-446 (56th ed., 2002). Morphine sulphate is preferably
15 administered in an initial dose of about 2 mg IV/SC/IM, depending on whether a patient has already taken narcotic analgesics. *See, e.g., Physicians' Desk Reference*, 594-595 (56th ed., 2002). No intrinsic limit to the amount that can be given exists, as long as a patient is observed for signs of adverse effects, especially respiratory depression. Various IV doses may be used, commonly titrated until a desired effect is obtained. For
20 patients not using long-term agents, as little as 2 mg IV/SC may be sufficient. Larger doses are typically required for patients taking long-term narcotic analgesics. Morphine sulphate are also available in oral form in immediate-release and timed-release preparations. The long-acting oral form may be administered twice per day. An immediate-release form may be needed for periods of pain break-through, with the dose
25 dependent on previous use. Oxycodone is a long-acting form of an opioid and may be used in initial and later stages of pain. Oxycodone is preferably administered in an amount of about 10-160 mg twice a day. *See, e.g., Physicians' Desk Reference*, 2912-2916 (56th ed., 2002). Meperidine is preferably administered in an amount of about 50-150 mg PO/IV/IM/SC every 3-4 hours. A typical pediatric dose of meperidine is 1-1.8
30 mg/kg (0.5-0.8 mg/lb) PO/IV/IM/SC every 3-4 hours. *See, e.g., Physicians' Desk Reference*, 3079-3081 (56th ed., 2002). Fentanyl transdermal patch is available as a transdermal dosage form. Most patients are administered the drug in 72 hour dosing intervals; however, some patients may require dosing intervals of about 48 hours. A typical adult dose is about 25 mcg/h (10 cm²), 50 mcg/h (20 cm²), 75 mcg/h (75 cm²), or
35 100 mcg/h (100 cm²). *See, e.g., Physicians' Desk Reference*, 1786-1789 (56th ed., 2002).

5 Non-narcotic analgesics and anti-inflammatories can be used to treat patients suffering from mild to moderate pain. Anti-inflammatories such as non-steroidal anti-inflammatory drugs (NSAIDs) and cox-2 inhibitors typically inhibit inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis. NSAIDs may provide pain relief in the early
10 stage of a pain syndrome. Examples of anti-inflammatories include, but are not limited to, salicylic acid acetate, ibuprofen, ketoprofen, rofecoxib, naproxen sodium, ketorolac, and other known conventional medications. Ibuprofen can be orally administered in an amount of 400-800 mg three times a day. *See, e.g., Physicians' Desk Reference*, 511, 667 and 773 (56th ed., 2002); *Physicians' Desk Reference for Nonprescription Drugs and*
15 *Dietary Supplements*, 511, 667, 773 (23rd ed., 2002). Naproxen sodium may also preferably be used for relief of mild to moderate pain in an amount of about 275 mg thrice a day or about 550 mg twice a day. *See, e.g., Physicians' Desk Reference*, 2967-2970 (56th ed., 2002). A specific cox-2 inhibitor is celecoxib.

Antidepressants, *e.g.*, nortriptyline, may also be used in embodiments of
20 the invention to treat patients suffering from chronic and/or neuropathic pain. Antidepressants increase the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibiting their reuptake by presynaptic neuronal membrane. Some antidepressants also have sodium channel blocking ability to reduce the firing rate of injured peripheral afferent fibers. Examples of antidepressants include, but are not
25 limited to, nortriptyline (Pamelor[®]), amitriptyline (Elavil[®]), imipramine (Tofranil[®]), doxepin (Sinequan[®]), clomipramine (Anafranil[®]), fluoxetine (Prozac[®]), sertraline (Zoloft[®]), nefazodone (Serzone[®]), venlafaxine (Effexor[®]), trazodone (Desyrel[®]), bupropion (Wellbutrin[®]) and other known conventional medications. *See, e.g., Physicians' Desk Reference*, 329, 1417, 1831 and 3270 (57th ed., 2003). The oral adult
30 dose is typically in an amount of about 25-100 mg, and preferably does not exceed 200 mg/d. A typical pediatric dose is about 0.1 mg/kg PO as initial dose, increasing, as tolerated, up to about 0.5-2 mg/d. Amitriptyline is preferably used for neuropathic pain in an adult dose of about 25-100 mg PO. *See, e.g., Physicians' Desk Reference*, 755, 1238, 1684 and 3495 (56th ed., 2002).

5 Anticonvulsant drugs may also be used in embodiments of the invention. Examples of anticonvulsants include, but are not limited to, carbamazepine, oxcarbazepine (Trileptal[®]), gabapentin (Neurontin[®]), phenytoin, sodium valproate, clonazepam, topiramate, lamotrigine, zonisamide, and tiagabine. *See, e.g., Physicians' Desk Reference*, 2563 (57th ed., 2003).

10 In one embodiment, a JNK Inhibitor and a second active agent are administered to a patient, preferably a mammal, more preferably a human, in a sequence and within a time interval such that the JNK Inhibitor can act together with the other agent to provide an increased benefit than if they were administered otherwise. For example, the second active agent can be administered at the same time or sequentially in
15 any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect. In one embodiment, the JNK Inhibitor and the second active agent exert their effect at times which overlap. Each second active agent can be administered separately, in any appropriate form and by any suitable route. In other
20 embodiments, the JNK Inhibitor is administered before, concurrently or after administration of the second active agent. Surgery can also be performed as a preventive measure or to relieve pain.

 In various embodiments, the JNK Inhibitor and the second active agent are administered less than about 1 hour apart, at about 1 hour apart, at about 1 hour to
25 about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24
30 hours apart or no more than 48 hours apart. In other embodiments, the JNK Inhibitor and the second active agent are administered concurrently.

 In other embodiments, the JNK Inhibitor and the second active agent are administered at about 2 to 4 days apart, at about 4 to 6 days apart, at about 1 week apart, at about 1 to 2 weeks apart, or more than 2 weeks apart.

5 In certain embodiments, the JNK Inhibitor and optionally the second active agent are cyclically administered to a patient. Cycling therapy involves the administration of a first agent for a period of time, followed by the administration of a second agent and/or third agent for a period of time and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more
10 of the therapies, avoid or reduce the side effects of one of the therapies, and/or improve the efficacy of the treatment.

 In certain embodiments, the JNK Inhibitor and optionally the second active agent are administered in a cycle of less than about 3 weeks, about once every two weeks, about once every 10 days or about once every week. One cycle can comprise the
15 administration of a JNK Inhibitor and optionally the second active agent by infusion over about 90 minutes every cycle, about 1 hour every cycle, about 45 minutes every cycle. Each cycle can comprise at least 1 week of rest, at least 2 weeks of rest, at least 3 weeks of rest. The number of cycles administered is from about 1 to about 12 cycles, more typically from about 2 to about 10 cycles, and more typically from about 2 to about 8
20 cycles.

 In yet other embodiments, the JNK Inhibitor is administered in metronomic dosing regimens, either by continuous infusion or frequent administration without extended rest periods. Such metronomic administration can involve dosing at constant intervals without rest periods. Typically the JNK Inhibitors, are used at lower
25 doses. Such dosing regimens encompass the chronic daily administration of relatively low doses for extended periods of time. In preferred embodiments, the use of lower doses can minimize toxic side effects and eliminate rest periods. In certain embodiments, the JNK Inhibitor is delivered by chronic low-dose or continuous infusion ranging from about 24 hours to about 2 days, to about 1 week, to about 2 weeks, to about
30 3 weeks to about 1 month to about 2 months, to about 3 months, to about 4 months, to about 5 months, to about 6 months. The scheduling of such dose regimens can be optimized by the skilled artisan.

 In other embodiments, courses of treatment are administered concurrently to a patient, *i.e.*, individual doses of the second active agent are administered separately
35 yet within a time interval such that the JNK Inhibitor can work together with the second

5 active agent. For example, one component can be administered once per week in combination with the other components that can be administered once every two weeks or once every three weeks. In other words, the dosing regimens are carried out concurrently even if the therapeutics are not administered simultaneously or during the same day.

10 The second active agent can act additively or, more preferably, synergistically with the JNK Inhibitor. In one embodiment, a JNK Inhibitor is administered concurrently with one or more second active agents in the same pharmaceutical composition. In another embodiment, a JNK Inhibitor is administered concurrently with one or more second active agents in separate pharmaceutical
15 compositions. In still another embodiment, a JNK Inhibitor is administered prior to or subsequent to administration of a second active agent. The invention contemplates administration of a JNK Inhibitor and a second active agent by the same or different routes of administration, *e.g.*, oral and parenteral. In certain embodiments, when a JNK Inhibitor is administered concurrently with a second active agent that potentially
20 produces adverse side effects including, but not limited to, toxicity, the second active agent can advantageously be administered at a dose that falls below the threshold that the adverse side effect is elicited.

4.2.2 Use With Physical Therapy or Psychological Therapy

In still another embodiment, this invention encompasses a method of treating,
25 preventing, modifying, and/or managing pain, which comprises administering a JNK Inhibitor in conjunction with physical therapy or psychological therapy.

Symptoms of pain include vasomotor dysfunction and movement disorders. A steady progression of gentle weight bearing to progressive active weight bearing is important in patients experiencing pain. Gradual desensitization to increasing sensory
30 stimuli may also be helpful. Gradual increase in normalized sensation tends to reset the altered processing in the CNS. Physical therapy can thus play an important role in functional restoration. The goal of physical therapy is to gradually increase strength and flexibility.

It is believed that the combined use of a JNK Inhibitor and physical therapy may
35 provide a unique treatment regimen that is unexpectedly effective in certain patients.

5 Without being limited by theory, it is believed that a JNK Inhibitor may provide additive or synergistic effects when given concurrently with physical therapy.

Much pain literature notes a concomitant behavioral and psychiatric morbidities such as depression and anxiety. It is believed that the combined use of a JNK Inhibitor and psychological treatment may provide a unique treatment regimen that is
10 unexpectedly effective in certain patients. Without being limited by theory, it is believed that a JNK Inhibitor may provide additive or synergistic effects when given concurrently with psychological therapy including, but not limited to, biofeedback, relaxation training, cognitive-behavioral therapy, and individual or family psychotherapy.

4.2.3 Use With Interventional Pain Management Techniques

15 In still another embodiment, this invention encompasses a method of treating, preventing, modifying, and/or managing pain, which comprises administering a JNK Inhibitor in conjunction with (*e.g.*, before, during, or after) Pain Management interventional techniques. Examples of Pain Management interventional techniques include, but are not limited to, the use of sympathetic blocks, intravenous regional
20 blocks, placement of dorsal column stimulators or placement of intrathecal infusion devices for analgesic medication delivery. Preferred Pain Management interventional techniques provides a selective neural blockade which interrupts the activity of the sympathetic nervous system in the region in which pain is experienced.

The combined use of the JNK Inhibitor and Pain Management
25 interventional techniques may provide a unique treatment regimen that is unexpectedly effective in certain patients. Without being limited by theory, it is believed that a JNK Inhibitor may provide additive or synergistic effects when given concurrently with Pain Management interventional techniques. An example of Pain Management interventional techniques is intravenous regional block using BIER block with a variety of agents such
30 as, but not limited to, local anesthetics such as bupivacaine, lidocaine, guanethidine, ketamine, bretylium, steroids, ketorolac, and reserpine. Perez, R.S., *et al.*, *J Pain Symptom Manage* 21(6):511-26 (2001). For pain involving the upper extremities, a stellate (cervicothoracic) ganglion block may be used. The invention also encompasses the use of a somatic block, which involves continuous epidural infusion along with

5 different variants of brachial plexus blocks. An axillary, supraclavicular, or
infraclavicular approach of the somatic block may also be useful.

4.3 PHARMACEUTICAL COMPOSITIONS

The compositions comprising a JNK Inhibitor include bulk-drug
compositions useful in the manufacture of pharmaceutical compositions (*e.g.*, impure or
10 non-sterile compositions) and pharmaceutical compositions (*i.e.*, compositions that are
suitable for administration to a patient) which can be used in the preparation of unit
dosage forms. Such compositions optionally comprise an effective amount of a JNK
Inhibitor or a combination of the JNK Inhibitors disclose herein and a pharmaceutically
acceptable vehicle, excipient or carrier. Preferably, compositions of the invention
15 comprise a prophylactically or therapeutically effective amount of JNK Inhibitor and
optionally a second active agent, and a pharmaceutically acceptable carrier. In one
embodiment, the second active agent is not an anti-cancer agent.

In a specific embodiment, the term “pharmaceutically acceptable” means
approved by a regulatory agency of the Federal or a state government or listed in the
20 U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and
more particularly in humans. The term “carrier” refers to a diluent, adjuvant, excipient,
or vehicle with which a JNK Inhibitor is administered. Such pharmaceutical vehicles
can be liquids, such as water and oils, including those of petroleum, animal, vegetable or
synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The
25 pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin,
colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening,
lubricating and coloring agents can be used. When administered to a patient, the
pharmaceutically acceptable vehicles are preferably sterile. Water can be the vehicle
when the JNK Inhibitor is administered intravenously. Saline solutions and aqueous
30 dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for
injectable solutions. Suitable pharmaceutical vehicles also include excipients such as
starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium
stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol,
propyleneglycol, water, ethanol and the like. The present compositions, if desired, can
35 also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

5 The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule (see *e.g.*, U.S. Patent No. 5,698,155). Other examples of suitable
10 pharmaceutical vehicles are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

 In a preferred embodiment, the JNK Inhibitor and optionally the a therapeutic or prophylactic agent are formulated in accordance with routine procedures as pharmaceutical compositions adapted for intravenous administration to human beings.
15 Typically, JNK Inhibitors for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for
20 example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the JNK Inhibitor is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the JNK Inhibitor is administered by injection, an ampoule of sterile water for injection
25 or saline can be provided so that the ingredients can be mixed prior to administration.

 Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions can contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring
30 agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving
35 compound are also suitable for an orally administered JNK Inhibitor. In these later

5 platforms, fluid from the environment surrounding the capsule is imbibed by the driving
compound, which swells to displace the agent or agent composition through an aperture.
These delivery platforms can provide an essentially zero order delivery profile as
opposed to the spiked profiles of immediate release formulations. A time delay material
such as glycerol monostearate or glycerol stearate can also be used. Oral compositions
10 can include standard vehicles such as mannitol, lactose, starch, magnesium stearate,
sodium saccharine, cellulose, magnesium carbonate, and the like. Such vehicles are
preferably of pharmaceutical grade.

Further, the effect of the JNK Inhibitor can be delayed or prolonged by
proper formulation. For example, a slowly soluble pellet of the JNK Inhibitor can be
15 prepared and incorporated in a tablet or capsule. The technique can be improved by
making pellets of several different dissolution rates and filling capsules with a mixture of
the pellets. Tablets or capsules can be coated with a film which resists dissolution for a
predictable period of time. Even the parenteral preparations can be made long-acting, by
dissolving or suspending the compound in oily or emulsified vehicles which allow it to
20 disperse only slowly in the serum.

4.4 FORMULATIONS

Pharmaceutical compositions for use in accordance with the present
invention can be formulated in conventional manner using one or more physiologically
acceptable carriers or excipients.

25 Thus, the JNK Inhibitor and optionally a second active agent, and their
physiologically acceptable salts and solvates, can be formulated into pharmaceutical
compositions for administration by inhalation or insufflation (either through the mouth or
the nose) or oral, parenteral or mucosal (such as buccal, vaginal, rectal, sublingual)
administration. In one embodiment, local or systemic parenteral administration is used.

30 For oral administration, the pharmaceutical compositions can take the
form of, for example, tablets or capsules prepared by conventional means with
pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinised maize
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose,
microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium
35 stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or

5 wetting agents (*e.g.*, sodium lauryl sulphate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as
10 suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (*e.g.*, methyl or propyl-*p*-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

15 Preparations for oral administration can be suitably formulated to give controlled release of the JNK Inhibitor.

For buccal administration the pharmaceutical compositions can take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the pharmaceutical compositions for use
20 according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a
25 metered amount. Capsules and cartridges of *e.g.*, gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The pharmaceutical compositions can be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations
30 for injection can be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The pharmaceutical compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable
35 vehicle, *e.g.*, sterile pyrogen-free water, before use.

5 The pharmaceutical compositions can also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

 In addition to the formulations described previously, the pharmaceutical compositions can also be formulated as a depot preparation. Such long acting
10 formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the pharmaceutical compositions can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

15 The invention also provides that a pharmaceutical composition can be packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity. In one embodiment, the pharmaceutical composition is supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can be reconstituted, *e.g.*, with water or saline to the appropriate concentration for
20 administration to a patient.

 The pharmaceutical compositions can, if desired, be presented in a pack or dispenser device that can contain one or more unit dosage forms containing the active ingredient. The pack can for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for
25 administration.

 In certain preferred embodiments, the pack or dispenser contains one or more unit dosage forms containing no more than the recommended dosage formulation as determined in the *Physician's Desk Reference* (56th ed. 2002, herein incorporated by reference in its entirety).

30 **4.5 ROUTES OF ADMINISTRATION**

 Methods of administering a JNK Inhibitor and optionally a second active agent include, but are not limited to, parenteral administration (*e.g.*, intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (*e.g.*, intranasal, rectal, vaginal, sublingual, buccal or oral routes). In a specific
35 embodiment, the JNK Inhibitor and optionally the second active agent are administered

5 intramuscularly, intravenously, or subcutaneously. The JNK Inhibitor and optionally the second active agent can also be administered by infusion or bolus injection and can be administered together with other biologically active agents. Administration can be local or systemic. The JNK Inhibitor and optionally the second active agent and their physiologically acceptable salts and solvates can also be administered by inhalation or
10 insufflation (either through the mouth or the nose). In one embodiment, local or systemic parenteral administration is used.

In specific embodiments, it can be desirable to administer the JNK Inhibitor locally to the area in need of treatment. This can be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, *e.g.*, in
15 conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of an atherosclerotic plaque tissue.

20 Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the JNK Inhibitor can be formulated as a suppository, with traditional binders and vehicles such as triglycerides.

25 In another embodiment, the JNK Inhibitor can be delivered in a vesicle, in particular a liposome (*see* Langer, 1990, *Science* 249:1527-1533; Treat *et al.*, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see* generally *ibid.*).

30 In yet another embodiment, the JNK Inhibitor can be delivered in a controlled release system. In one embodiment, a pump can be used (*see* Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald *et al.*, 1980, *Surgery* 88:507 Saudek *et al.*, 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release,
35 Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug

5 Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley,
New York (1984); Ranger and Peppas, 1983, *J. Macromol. Sci. Rev. Macromol. Chem.*
23:61; *see also* Levy *et al.*, 1985, *Science* 228:190; During *et al.*, 1989, *Ann. Neurol.*
25:351; Howard *et al.*, 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a
controlled-release system can be placed in proximity of the target of the JNK Inhibitor,
10 *e.g.*, the liver, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, in
Medical Applications of Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)). Other
controlled-release systems discussed in the review by Langer, 1990, *Science* 249:1527-
1533) can be used.

4.6 DOSAGES

15 The amount of the JNK Inhibitor that is effective in the treatment,
prevention, management and/or modification of pain can be determined by standard
research techniques. For example, the dosage of the JNK Inhibitor which will be
effective in the treatment, prevention, management and/or modification of pain can be
determined by administering the JNK Inhibitor to an animal in a model such as, *e.g.*, the
20 animal models known to those skilled in the art. In addition, *in vitro* assays can
optionally be employed to help identify optimal dosage ranges.

Selection of a particular effective dose can be determined (*e.g.*, via
clinical trials) by a skilled artisan based upon the consideration of several factors which
will be known to one skilled in the art. Such factors include the disease to be treated or
25 prevented, the symptoms involved, the patient's body mass, the patient's immune status
and other factors known by the skilled artisan.

The precise dose to be employed in the formulation will also depend on
the route of administration, and the seriousness of the pain, and should be decided
according to the judgment of the practitioner and each patient's circumstances. Effective
30 doses can be extrapolated from dose-response curves derived from *in vitro* or animal
model test systems.

The dose of a JNK Inhibitor to be administered to a patient, such as a
human, is rather widely variable and can be subject to independent judgment. It is often
practical to administer the daily dose of a JNK Inhibitor at various hours of the day.
35 However, in any given case, the amount of a JNK Inhibitor administered will depend on

5 such factors as the solubility of the active component, the formulation used, patient condition (such as weight), and/or the route of administration.

In one embodiment, the general range of effective amounts of the JNK Inhibitor alone or in combination with a second active agent are from about 0.001 mg/day to about 1000 mg/day, more preferably from about 0.001 mg/day to 750 mg/day, 10 more preferably from about 0.001 mg/day to 500 mg/day, more preferably from about 0.001 mg/day to 250 mg/day, more preferably from about 0.001 mg/day to 100 mg/day, more preferably from about 0.001 mg/day to 75 mg/day, more preferably from about 0.001 mg/day to 50 mg/day, more preferably from about 0.001 mg/day to 25 mg/day, more preferably from about 0.001 mg/day to 10 mg/day, more preferably from about 15 0.001 mg/day to 1 mg/day. In another embodiment, the general range of effective amounts of the JNK Inhibitor alone or in combination with a second active agent are from about 50 mg/day to about 1500 mg/day, more preferably from about 50 mg/day to 1000 mg/day, more preferably from about 100 mg/day to 400 mg/day. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of 20 the day. However, in any given case, the amount of compound administered will depend on such factors as the solubility of the active component, the formulation used, subject condition (such as weight), and/or the route of administration. In certain embodiments, the JNK Inhibitor can be administered daily, every other day, several times a week, weekly, bi-weekly or monthly.

25 4.7 KITS

The invention provides a pharmaceutical pack or kit comprising one or more containers containing a JNK Inhibitor and optionally one or more second active agents useful for the treatment, prevention, management and/or modification of pain. The invention also provides a pharmaceutical pack or kit comprising one or more 30 containers containing one or more of the ingredients of the pharmaceutical compositions. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration; or instructions for the composition's use.

5 The present invention provides kits that can be used in the above methods.
In one embodiment, a kit comprises a JNK Inhibitor, in one or more containers, and
optionally one or more second active agents useful for the treatment, prevention or
management of pain, in one or more additional containers.

5. **EXAMPLES**

10 The following examples illustrate certain aspects of the invention, but do
not limit its scope.

 The JNK Inhibitors can be tested for their ability to treat, prevent, manage
and/or modify pain by any pain model well-known in the art. A variety of animal pain
models are described in Hogan, Q., *Regional Anesthesia and Pain Medicine* 27(4):385-
15 401 (2002), which is incorporated by reference herein in its entirety.

 Examples of nociceptive pain models include the formalin test, the hot-
plate test and the tail-flick test. These are useful models for injury-induced pain.

 An illustrative example of the formalin test is set forth herein in Example
5.1. Briefly, formalin is injected into the plantar surface of a hind paw, and the
20 effectiveness of the test compound is determined by recording the number of pain-
associated behaviours observed over a period of time for a particular dose of the test
compound. Abbott, F. *et al. Pain* 60:91-102 (1995).

 An illustrative example of the hot-plate test is set forth herein in Example
5.2. Briefly, an animal is administered a test compound followed by observation of the
25 length of time before the animal reacts to the heat stimulus of the hot plate. Malmberg,
A. and Yaksh, T., *Pain* 60:83-90 (1995).

 An illustrative example of the tail-flick test is set forth herein in Example
5.3. Briefly, an animal is administered a test compound followed by observation of the
length of time before the animal reacts to the stimulus of a focused beam of light on its
30 tail.

 The most commonly used neuropathic pain models are the Bennett,
Selzer, and Chung models. Siddall, P.J. and Munglani, R., *Animal Models of Pain*, pp
377-384 in Bountra, C., Munglani, R., Schmidt, W.K., eds. Pain: Current Understanding,
Emerging Therapies and Novel Approaches to Drug Discovery, Marcel Dekker, Inc.,

5 New York, 2003. The Bennett and Selzer models are well-known and rapid to perform. The Chung model is robust for mechanical allodynia in most animals and is well characterized though complicated.

The capsaicin model as described herein in Example 5.4 may be appropriate for agents to be used to treat hyperalgesia and allodynia (*e.g.*, vanilloid
10 receptor 1 (VR1) antagonists and AMPA antagonists), whereas UV skin burn may be appropriate for bradykinin B1 receptor antagonists, cannabinoid agonists, and VR1 antagonists. Clinical applications of the capsaicin model have supported the antihyperalgesic effects of several clinically used drugs such as opioids, local anesthetics, ketamine and gabapentin. Visceral models have, as yet, unknown potential
15 as hyperalgesic models and require validation.

These models represent a range of approaches to try and mimic some of the damage and dysfunction in clinical conditions. There are also animal models for diseases associated with pain, such as diabetic neuropathy or the new bone cancer and visceral pain models

20 A drawback with animal models is that they can only measure evoked pain. Hyperalgesia is most commonly measured. No animal model is able to measure spontaneous pain, which is of the most concerning in connection with clinical pain states.

25 **5.1 FORMALIN TEST FOR THE MEASUREMENT OF PERSISTENT PAIN IN RATS**

Animals are injected with the a JNK Inhibitor or vehicle (controls) followed by the injection of formalin into the dorsal surface of the paw. The animal is observed to determine the number of times it flinches the injected paw, over a period of 60 minutes. This model allows for the evaluation of anti-nociceptive drugs in the
30 treatment of pain.

Animals are contained in shoe box cages for the duration of the experiment. Formalin (50µl; 0.5%) is injected into the dorsal surface of the rear, right paw, by placing the needle (28.5G) above the toes and below the ankle and inserting it beneath the surface of the skin. A timer is started immediately after the injection to mark
35 the beginning of phase 1. The animal is observed for 10 minutes after injection and the

5 number of times it flinches the injected paw are counted. Thirty minutes after the first formalin injection, phase 2 begins. Flinches are counted as in phase 1 for the next 20 minutes. A JNK Inhibitor is administered up to 24 hrs prior to the formalin test, by either oral, i.p., i.v. or s.c. routes of administration. Animals are repeated in the order they were treated. Immediately following the completion of the test periods, animals are euthanized
10 by CO₂ asphyxiation in accordance with IACUC guidelines.

Any animal experiencing unanticipated events at any time point throughout this study is evaluated for veterinary intervention. Any animal that cannot recover with standard veterinary care is euthanized immediately by CO₂ asphyxiation in accordance with IACUC guidelines.

15 **5.2 HOT-PLATE TEST FOR MEASUREMENT OF ACUTE PAIN IN RATS**

Animals are injected with a JNK Inhibitor or vehicle (controls) and then placed on the hot plate one at a time. Latency to respond to the heat stimulus is measured by the amount of time it takes for the animal to lick one of its paws. This model allows
20 for the evaluation of anti-nociceptive drugs in the treatment of pain (*See, Langerman et al., Pharmacol. Toxicol. Methods 34:23-27 (1995)*).

Morphine treatment is used to determine the optimal hotplate temperature. Doses of 8 to 10 mg/kg morphine (i.p.) provide a near-maximal anti-nociceptive response in acute pain assays. The apparatus is set to the temperature at which this type
25 of anti-nociceptive response is observed with these doses of morphine (approximately 55°C). A JNK Inhibitor is dosed up to 24 hrs prior to the hot-plate test, by either oral, i.p., i.v. or s.c. routes of administration. When the post-treatment time has elapsed, individual testing of animals is begun. A single animal is placed on the hot plate and a stopwatch or timer is immediately started. The animal is observed until it shows a
30 nociceptive response (*e.g.*, licks its paw) or until the cut-off time of 30 seconds is reached (to minimize tissue damage that can occur with prolonged exposure to a heated surface). The animal is removed from the hot-plate and its latency time to respond is recorded. For animals that do not respond prior to the cut-off time, the cut-off time will be recorded as their response time. Animals are repeated in the order they were treated.

5 Animals are euthanized immediately following the experiment by CO₂ asphyxiation in accordance with IACUC guidelines.

Any animal experiencing unanticipated events at any time point throughout this study is evaluated for veterinary intervention. Any animal that cannot recover with standard veterinary care is euthanized immediately by CO₂ asphyxiation in
10 accordance with IACUC guidelines.

5.3 TAIL-FLICK TEST FOR MEASUREMENT OF ACUTE PAIN IN RATS

Animals are injected with the a JNK Inhibitor or vehicle (controls) and then a light beam is focused on the tail. Latency to respond to the stimulus is measured
15 by the amount of time it takes for the animal to flick its tail. This model allows for the evaluation of anti-nociceptive drugs in the treatment of pain (*See, Langerman et al., Pharmacol. Toxicol. Methods 34:23-27 (1995)*).

A JNK Inhibitor is dosed up to 24 hrs prior to the tail flick test, by either oral, i.p., i.v. or s.c. routes of administration according with the IACUC guidelines.
20 When the post-treatment time has elapsed, individual testing of animals is begun. A single animal is placed on a tail flick apparatus exposing the ventral tail surface to a focused light beam. Response latency is the time from the application of the light until the tail is flicked. The animal is observed until it shows a nociceptive response (*e.g.*, tail flick) or until the cut-off time of 10 seconds is reached (to minimize tissue damage that
25 can occur with prolonged exposure to a heated surface). The animal is removed from the light source, its latency time to respond is recorded and then the animal is euthanized immediately by CO₂ asphyxiation in accordance with IACUC guidelines. The light beam intensity is adjusted to produce a baseline latency of 2.5-4 seconds. For animals that do not respond prior to the cut-off time, the cut-off time is recorded as their response
30 time. Animals are repeated in the order they were treated.

Any animal experiencing unanticipated events at any time point throughout this study is evaluated for veterinary intervention. Any animal that cannot recover with standard veterinary care is euthanized immediately by CO₂ asphyxiation in accordance with IACUC guidelines.

5 **5.4 MODEL FOR TOPICAL CAPSAICIN-INDUCED
THERMAL ALLODYNIA**

A model particularly useful for thermal allodynia is the topical capsaicin-induced thermal allodynia model. Butelman, E.R. *et al.*, *J. of Pharmacol. Exp. Therap.* 306:1106-1114 (2003). This model is a modification of the warm water tail withdrawal
10 model. Ko, M.C. *et al.*, *J. of Pharmacol. Exp. Therap.* 289:378-385 (1999).

Briefly, monkeys sit in a custom made chair in a temperature-controlled room (20-22°C). Their tails are shaved with standard clippers and tail withdrawal latencies are timed in 0.1 second increments up to a maximum of 20 seconds in both 38°C and 42°C water stimuli to provide a baseline. Following baseline determination,
15 the tail is gently dried and degreased with an isopropyl alcohol pad.

Approximately 15 minutes before use, capsaicin is dissolved in a vehicle composed of 70% ethanol and 30% sterile water for a final capsaicin concentration of either 0.0013 or 0.004 M. The solution (0.3 mL) is slowly injected onto a gauze patch, saturating the patch and avoiding overflow. Within 30 seconds of the capsaicin solution
20 being added to the patch, capsaicin patch is fastened to the tail with tape. After 15 minutes, the patch is removed and tail withdrawal testing in both 38°C and 42°C water stimuli is performed as described above.

Allodynia is detected as a decrease in tail withdrawal latency compared to the baseline measurements. To determine the ability of a JNK Inhibitor to decrease
25 allodynia, a single dose of the compound is administered prior to (*e.g.*, 15 minutes prior, 30 minutes prior, 60 minutes prior or 90 minutes prior) the application of the capsaicin patch. Alternatively, the allodynia reversal properties of a JNK Inhibitor can be determined by administering a single dose of the compound after application of the capsaicin patch (*e.g.*, immediately after, 30 minutes after, 60 minutes after or 90 minutes
30 after).


5.5 JNK INHIBITOR ACTIVITY ASSAYS

The ability of a JNK Inhibitor to inhibit JNK and accordingly, to be useful for the treatment, prevention, management and/or modification of pain, can be demonstrated using one or more of the following assays.

35

5

5.5.1 Example: Biological Activity of 5-amino-anthra(9,1-*cd*)isothiazol-6-one



JNK Assay

10 To 10 μL of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in 20% DMSO/80%
dilution buffer containing of 20 mM HEPES (pH 7.6), 0.1 mM EDTA, 2.5 mM
magnesium chloride, 0.004% Triton x100, 2 $\mu\text{g/mL}$ leupeptin, 20 mM β -
glycerolphosphate, 0.1 mM sodium vanadate, and 2 mM DTT in water was added 30 μL
of 50-200 ng His6-JNK1, JNK2, or JNK3 in the same dilution buffer. The mixture was
15 pre-incubated for 30 minutes at room temperature. Sixty microliter of 10 μg GST-c-
Jun(1-79) in assay buffer consisting of 20 mM HEPES (pH 7.6), 50 mM sodium
chloride, 0.1 mM EDTA, 24 mM magnesium chloride, 1 mM DTT, 25 mM PNPP,
0.05% Triton x100, 11 μM ATP, and 0.5 μCi γ -32P ATP in water was added and the
reaction was allowed to proceed for 1 hour at room temperature. The c-Jun
20 phosphorylation was terminated by addition of 150 μL of 12.5% trichloroacetic acid.
After 30 minutes, the precipitate was harvested onto a filter plate, diluted with 50 μL of
the scintillation fluid and quantified by a counter. The IC_{50} values were calculated as the
concentration of 5-amino-anthra(9,1-*cd*)isothiazol-6-one at which the c-Jun
phosphorylation was reduced to 50% of the control value. Compounds that inhibit JNK
25 preferably have an IC_{50} value ranging 0.01 - 10 μM in this assay. 5-Amino- anthra(9,1-
cd)isothiazol-6-one has an IC_{50} according to this assay of 1 μM for JNK2 and 400 nM for
JNK3. The measured IC_{50} value for 5-amino-anthra(9,1-*cd*)isothiazol-6-one, as
measured by the above assay, however, shows some variability due to the limited
solubility of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in aqueous media. Despite the
30 variability, however, the assay consistently does show that 5-amino-anthra(9,1-
cd)isothiazol-6-one inhibits JNK. This assay demonstrates that 5-amino-anthra(9,1-
cd)isothiazol-6-one, an illustrative JNK Inhibitor, inhibits JNK2 and JNK3 and,

5 accordingly, is useful for the treatment, prevention, management and/or modification of pain.

Selectivity For JNK:

10 5-Amino-anthra(9,1-*cd*)isothiazol-6-one was also assayed for its inhibitory activity against several protein kinases, listed below, using techniques known to those skilled in art (*See, e.g.*, Protein Phosphorylation, Sefton & Hunter, Eds., Academic Press, pp. 97-367, 1998). The following IC₅₀ values were obtained:

	<u>Enzyme</u>	<u>IC₅₀</u>
	p38-2	>30,000 nM
15	MEK6	>30,000 nM
	LKK1	>30,000nM
	IKK2	>30,000nM

20 This assay shows that 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, selectively inhibits JNK relative to other protein kinases and, accordingly, is a selective JNK Inhibitor. Therefore, 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, is useful for the treatment, prevention, management and/or modification of pain.

25 Jurkat T-cell IL-2 Production Assay:

Jurkat T cells (clone E6- 1) were purchased from the American Type Culture Collection of Manassas, VA and maintained in growth media consisting of RPMI 1640 medium containing 2 mM L-glutamine (commercially available from Mediatech Inc. of Herndon, VA), with 10% fetal bovine serum (commercially available from Hyclone Laboratories Inc. of Omaha, NE) and penicillin/streptomycin. All cells
30 were cultured at 37°C in 95% air and 5% CO₂. Cells were plated at a density of 0.2 x 10⁶ cells per well in 200 µL of media. Compound stock (20 mM) was diluted in growth media and added to each well as a 10x concentrated solution in a volume of 25 µL, mixed, and allowed to pre-incubate with cells for 30 minutes. The compound vehicle
35 (dimethylsulfoxide) was maintained at a final concentration of 0.5% in all samples. After 30 minutes the cells were activated with PMA (phorbol myristate acetate, final

5 concentration 50 ng/mL) and PHA (phytohemagglutinin, final concentration 2 μ g/mL). PMA and PHA were added as a 10x concentrated solution made up in growth media and added in a volume of 25 μ L per well. Cell plates were cultured for 10 hours. Cells were pelleted by centrifugation and the media removed and stored at -20°C. Media aliquots are analyzed by sandwich ELISA for the presence of IL-2 as per the manufacturers
10 instructions (Endogen Inc. of Woburn, MA). The IC₅₀ values were calculated as the concentration of 5-amino-anthra(9,1-*cd*)isothiazol-6-one at which the IL-2 production was reduced to 50% of the control value. Compounds that inhibit JNK preferably have an IC₅₀ value ranging from 0.1 - 30 μ M in this assay. 5-Amino-anthra(9,1-*cd*)isothiazol-6-one has an IC₅₀ of 30 μ M. The measured IC₅₀ value for 5-amino-anthra(9,1-
15 *cd*)isothiazol-6-one, as measured by the above assay, however, shows some variability due to the limited solubility of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in aqueous media. Despite the variability, however, the assay consistently does show that 5-amino-anthra(9,1-*cd*)isothiazol-6-one inhibits JNK.

This assay shows that 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an
20 illustrative JNK Inhibitor, inhibits IL-2 production in Jurkat T-cells and accordingly inhibits JNK. Therefore, 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, is useful for the treatment, prevention, management and/or modification of pain.

25 [³H]Dopamine Cell Culture Assay:

Cultures of dopaminergic neurons were prepared according to a modification of the procedure described by Raymon and Leslie (*J. Neurochem.* 62:1015-1024, 1994). Time-mated pregnant rats were sacrificed on embryonic day 14 - 15 (crown rump length 11 - 12 mm) and the embryos removed by cesarean section. The ventral
30 mesencephalon, containing the dopaminergic neurons, was dissected from each embryo. Tissue pieces from approximately 48 embryos were pooled and dissociated both enzymatically and mechanically. An aliquot from the resulting cell suspension was counted and the cells were plated in high glucose DMEM/F12 culture medium with 10% fetal bovine serum at a density of 1 x 10⁵ cells/well of a Biocoat poly-D-lysine-coated 96-
35 well plate. The day following plating was considered 1 day *in vitro* (DIV). Cells were maintained in a stable environment at 37°C, 95% humidity, and 5% CO₂. A partial

5 medium change was performed at 3 DIV. At 7 DIV, cells were treated with the neurotoxin, 6-hydroxydopamine (6-OHDA, 30 μ M) in the presence and absence of 5-amino-anthra(9,1-*cd*)isothiazol-6-one. Cultures were processed for [3 H]dopamine uptake 22 hours later.

[3 H]Dopamine uptake is used as a measure of the health and integrity of
10 dopaminergic neurons in culture (Prochiantz et al., *PNAS* 76: 5387-5391, 1979). It was used in these studies to monitor the viability of dopaminergic neurons following exposure to the neurotoxin 6-OHDA. 6-OHDA has been shown to damage dopaminergic neurons both *in vitro* and *in vivo* and is used to model the cell death observed in Parkinson's disease (Ungerstedt, U., *Eur. J. Pharm.*, 5 (1968) 107-110 and
15 Hefti et al., *Brain Res.*, 195 (1980) 123-137). Briefly, cells treated with 6-OHDA in the presence and absence of 5-amino-anthra(9,1-*cd*)isothiazol-6-one were assessed in the uptake assay 22 hrs after exposure to 6-OHDA. Culture medium was removed and replaced with warm phosphate buffered saline (PBS) with calcium and magnesium, 10 μ M pargyline, 1 mM ascorbic acid, and 50 nM [3 H]dopamine. Cultures were incubated
20 at 37°C for 20 min. Radioactivity was removed and the cultures were washed 3x with ice cold PBS. To determine the intracellular accumulation of [3 H]dopamine, cells were lysed with M-PER detergent and an aliquot was taken for liquid scintillation counting. The measured effect of 5-amino-anthra(9,1-*cd*) isothiazol-6-one on the intracellular accumulation of [3 H]dopamine, as measured by the above assay, however, shows some
25 variability due to the limited solubility of 5-amino-anthra(9,1-*cd*)isothiazol-6-one in aqueous media. Despite the variability, however, the assay consistently does show that 5-amino-anthra(9,1-*cd*)isothiazol-6-one protects rat ventral mesencephalan neurons from the toxic effects of 6-OHDA. Accordingly, 5-amino-anthra(9,1-*cd*)isothiazol-6-one, an illustrative JNK Inhibitor, is useful for the treatment, prevention, management and/or
30 modification of pain.

Brain-Blood Plasma Distribution of 5-amino-anthra(9,1-*cd*)isothiazol-6-one *In Vivo*

5-Amino-anthra(9,1-*cd*)isothiazol-6-one was administered intravenously (10 mg/kg) into the veins of Sprague-Dawley rats. After 2 hr, blood samples were
35 obtained from the animals and their vascular systems were perfused with approximately 100 mL of saline to rid their brains of blood. The brains were removed from the animals,

5 weighed, and homogenized in a 50 mL conical tube containing 10 equivalents (w/v) of
methanol/saline (1:1) using a Tissue Tearer (Fischer Scientific). The homogenized
material was extracted by adding 600 μ L of cold methanol to 250 μ L of brain
homogenate vortexed for 30 sec and subjected to centrifugation for 5 min. After
centrifugation, 600 μ L of the resulting supernatant was transferred to a clean tube and
10 evaporated at room temperature under reduced pressure to provide a pellet. The resulting
pellet was reconstituted in 250 μ L of 30% aqueous methanol to provide a brain
homogenate analysis sample. A plasma analysis sample was obtained using the brain
homogenate analysis sample procedure described above by substituting plasma for brain
homogenate. Standard plasma samples and standard brain homogenate samples
15 containing known amounts of 5-amino-anthra(9,1-*cd*)isothiazol-6-one were also
prepared by adding 5 μ L of serial dilutions (50:1) of a solution of 5-amino-anthra(9,1-*cd*)isothiazol-6-one freshly prepared in cold ethanol to 250 μ L of control rat plasma
(Bioreclamation of Hicksville, NY) or control brain homogenate. The standard plasma
samples and standard brain homogenate samples were then subjected to the same
20 extraction by protein precipitation, centrifugation, evaporation, and reconstitution
procedure used for the brain homogenate to provide brain homogenate standard analysis
samples and plasma standard analysis samples. The brain homogenate analysis samples,
plasma analysis samples, and standard analysis samples were analyzed and compared
using HPLC by injecting 100 μ L of a sample onto a 5 μ m C-18 Luna column (4.6 mm x
25 150 mm, commercially available from Phenomenex of Torrance, CA) and eluting at 1
mL/min with a linear gradient of 30% aqueous acetonitrile containing 0.1%
trifluoroacetic acid to 90% aqueous acetonitrile containing 0.1% trifluoroacetic acid over
8 minutes and holding at 90% aqueous acetonitrile containing 0.1% trifluoroacetic acid
for 3 min. with absorbance detection at 450 nm. Recovery of 5-amino-anthra(9,1-*cd*)isothiazol-6-one was $56 \pm 5.7\%$ for plasma and $42 \pm 6.2\%$ for the brain. The
30 concentration of 5-amino-anthra(9,1-*cd*) isothiazol-6-one in the brain and plasma was
determined by comparing HPLC chromatograms obtained from the brain homogenate
analysis samples and plasma analysis samples to standard curves constructed from
analysis of the brain homogenate standard analysis samples and the plasma standard
35 analysis samples, respectively. Results from this study show that 5-amino-anthra(9,1-

5 *cd*)isothiazol-6-one, following intravenous administration, crosses the blood-brain barrier to a significant extent. In particular, brain-drug concentrations were approximately 65 nmole/g and plasma concentrations were approximately 7 μ M at 2 hr post-dose, resulting in a brain-plasma concentration ratio of approximately 9-fold (assuming 1 g of brain tissue is equivalent to 1 mL of plasma). This example shows that 5-amino-anthra(9,1-
10 *cd*)isothiazol-6-one, an illustrative JNK Inhibitor, has enhanced ability to cross the blood-brain barrier. In addition, this example shows that the JNK Inhibitors, in particular 5-amino-anthra(9,1-*cd*)isothiazol-6-one, can cross the blood-brain barrier when administered to a patient.

 It will be appreciated that, although specific embodiments of the invention
15 have been described herein for purposes of illustration, the invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed. These embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and
20 described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

 A number of references have been cited, the entire disclosure of which are incorporated herein by reference in their entirety.